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ADENYLYL CYCLASE TYPE 9: REGULATION AND CARDIAC FUNCTION  
Tanya A. Baldwin, B.S. 
Advisory Professor: Carmen W. Dessauer, Ph.D. 
Abnormalities in cardiac stress signaling underlie a number of cardiovascular 
diseases (e.g. arrhythmias and heart failure). Cardiac stress signaling pathways 
normally integrate signals from the sympathetic nervous system to promote efficient 
contraction and relaxation under stress. Sympathetic control through β-adrenergic 
stimulation is propagated by adenylyl cyclase (AC). AC synthesizes cyclic AMP 
(cAMP), an important second messenger that initiates signaling pathways to modulate 
physiological and pathophysiological functions of the heart, including the activation 
of PKA and subsequent phosphorylation of ion channels, contractile machinery, and 
stress response proteins that enhance cardiac function. Alterations of cAMP signaling 
occur in the failing heart and contribute to impaired function. Of the AC isoforms 
present in adult cardiomyocytes (AC 4, 5, 6, and 9), AC9 is the most divergent in 
sequence and understudied. The work presented in this dissertation sought to 
evaluate the direct regulatory properties of AC9 and explores roles for AC9 in heart. 
To clarify conflicting reports for AC9 regulation, proposed regulators were 
systematically evaluated, including G-proteins, protein kinases, and forskolin utilizing 
in vitro and cell based assays. Overall, I conclude that most G-proteins or protein 
kinases do not directly regulate AC9, except Gαs, in vitro. Although AC9 is forskolin 
insensitive alone, weak activation by forskolin in the presence of Gαs is possible. AC9 
shows significant homodimerization and modest heterodimerization with AC5/6, which 
may account for the conflicting reports surrounding the regulation of this AC isoform. 
 
viii 
 
To study the role of AC9 in heart, a mouse model of AC9 genetic deletion was 
utilized. Although deletion of AC9 reduces less than 3% of total AC activity in heart, 
Yotiao-associated AC activity is eliminated. AC9-/- mice exhibit no structural 
abnormalities but show a significant bradycardia and alterations in Doppler 
echocardiography indicative of grade 1 diastolic dysfunction with preserved ejection 
fraction. Identification of novel AC9 binding partners, including the small heat shock 
protein 20 (Hsp20) and Popeye domain containing (Popdc) proteins may contribute to 
the underlying mechanisms of AC9-/- phenotypes. Collectively, this work suggests that 
AC9 forms distinct macromolecular complexes that contribute to local cAMP pools 
important for driving physiological function of the heart. 
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Chapter 1           
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures and text are partially reprinted from Baldwin, T. A., and C. W. Dessauer. 2018. 
Function of Adenylyl Cyclase in Heart: the AKAP Connection. J Cardiovasc Dev Dis 5. 
This is an open access article distributed under the Creative Commons Attribution 
License (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/.   
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The heart continuously balances the interplay of various signaling mechanisms in 
order to maintain homeostasis and to respond to stress. One pathway that contributes 
to cardiac physiology and stress is the cyclic adenosine monophosphate (cAMP) 
pathway. cAMP is a universal second messenger that integrates input from G-protein 
coupled receptors to coordinate subsequent intracellular signaling. Synthesis of cAMP 
from adenosine triphosphate (ATP) is controlled by the enzyme adenylyl cyclase (AC) 
(Rall and Sutherland, 1958). In the heart, cAMP acts downstream on a variety of 
effectors including protein kinase A (PKA), hyperpolarization-activated cyclic nucleotide 
gated channels (HCN), exchange protein directly activated by cAMP (EPAC), Popdc 
proteins, and a fraction of phosphodiesterase (PDEs). PKA is the best known and 
studied cAMP effector. PKA phosphorylation of intracellular targets coordinates a 
number of physiological outputs including contraction (Antos et al., 2001; Fink et al., 
2001) and relaxation (Zhang et al., 1995). HCN channel regulation by cAMP maintains 
basal heart rate (Alig et al., 2009) while EPAC facilitates calcium handling and cardiac 
hypertrophy (Metrich et al., 2010). PDEs degrade cAMP, further defining the temporal 
regulation of the signal. The most recently discovered cAMP effector, Popdc, is 
important for heart rate dynamics through regulation of the potassium channel, TREK1 
(Schindler and Brand, 2016).   
The AC family is composed of nine membrane bound isoforms (AC 1-9) and one 
soluble isoform (sAC). All of the isoforms can be found in the heart with the exception 
of AC8 (Sadana and Dessauer, 2009; Willoughby and Cooper, 2007). Cardiac 
fibroblasts express AC’s 2-7 (Ostrom et al., 2003), while in adult cardiac myocytes AC5 
and AC6 are considered the major isoforms (Iwatsubo et al., 2004; Okumura et al., 
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2003a). Lower levels of AC2, AC4 and AC9 are reported in myocytes (Li et al., 2012; 
Ping et al., 1997). 
1.1 ACs and their role in cardiac function: KO phenotypes 
AC5 and AC6 are closely related isoforms that share similar regulatory mechanisms, 
including inhibition by Gαi as the hallmark of this group; however, physiologically they 
appear to play distinct roles in cardiac function (Efendiev and Dessauer, 2011; Sadana 
and Dessauer, 2009). Additional modes of regulation for AC5/6 are extensively reviewed 
elsewhere (Dessauer et al., 2017). AC5 and AC6 are differentially expressed in 
development, with age, and in pressure overload models of cardiac hypertrophy. 
Additionally, an increase in AC5 protein is observed in neonatal hearts and models of 
heart disease (Hu et al., 2009; Scarpace et al., 1996). Another potential distinction 
between these two isoforms is their subcellular localization (Timofeyev et al., 2013). 
Several overexpression and deletion studies have focused on roles of these 
isoforms in cardiac function. Two independent AC5 deletion (AC5-/-) mouse lines have 
been generated. Overall, deletion of AC5 decreases total cAMP activity in cardiac 
membranes and isolated myocytes (~35-40%) under basal and stimulated 
(isoproterenol and forskolin) conditions (Okumura et al., 2003b; Tang et al., 2006). The 
two studies reported varying results for changes in cardiac function. Okumura et al. 
(Okumura et al., 2003b) observed a decrease in isoproterenol-stimulated left ventricular 
(LV) ejection fraction (LVEF) but no alterations in basal cardiac function (with 
intravenous isoproterenol). Conversely, Tang et al. (Tang et al., 2006) noted basal 
changes in contractile function of perfused isolated hearts in addition to a decreased 
sensitivity to β1-adrenergic receptor agonist. The most notable finding of AC5-/- mice was 
the effect on parasympathetic regulation of cAMP. Inhibition of cAMP production by Gi-
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coupled acetylcholine treatment was ablated and Ca2+ mediated inhibition was 
significantly reduced upon AC5 deletion (Okumura et al., 2003b). Physiologically, this 
corresponds to a reduction in LVEF and heart rate in response to muscarinic agonists 
and an attenuation of baroreflexes (Okumura et al., 2003b; Tang et al., 2006). Similarly, 
AC6 deletion results in a significant reduction of cAMP production in stimulated left 
ventricular homogenates or in cardiac myocytes (60-70%), with no changes to basal 
cAMP production (Tang et al., 2008). AC6 deletion revealed a number of unique 
contributions not observed in AC5-/-, including impaired calcium handling which results 
in depressed LV function (Tang et al., 2008). Furthermore, levels of AC6, but not AC5, 
limit βAR signaling in heart (Gao et al., 1998; Tepe et al., 1999).    
In addition to cardiac contractility, AC5 and AC6 play important roles with regard to 
cardiac stress. Deletion of AC5 is protective in a number of models of cardiac stress, 
including transverse aorta constriction, chronic isoproterenol infusion, age-related 
cardiomyopathy, and high fat diet, but not overexpression of Gq (Okumura et al., 2003b; 
Okumura et al., 2007; Timofeyev et al., 2010; Yan et al., 2007). While knockout of AC5 
can be beneficial to heart, overexpression of AC6 in heart infers protection in response 
to myocardial ischemia or dilated cardiomyopathy (Lai et al., 2008; Roth et al., 2002; 
Roth et al., 1999), but not chronic pressure overload using transverse aortic constriction 
(Guellich et al., 2010). However, the protection provided upon AC6 overexpression is 
independent of its catalytic activity, as expression of catalytically inactive AC6 is also 
cardioprotective (Gao et al., 2017), but requires proper localization via the N-terminus 
of AC6 (Wu et al., 2017). In fact, expression of AC6 using adenoviral vectors for 
treatment of heart disease is currently in clinical trials (Hammond et al., 2016). 
Therefore, it is tempting to simplify the system and suggest that AC5 is largely 
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associated with stress responses while AC6 is necessary for calcium handling and 
contractility. For these reasons, there has been considerable interest in AC5-selective 
inhibitors for treatment of heart disease. However, deletion of AC6 can also be protective 
from chronic pressure overload in female, but not in male mice (Tang et al., 2010); 
therefore, roles for AC isoforms may depend on the type of heart disease model. AC 
inhibitors such as Ara-A (Vidarabine) do have benefits for treatment of myocardial 
ischemia when delivered after coronary artery reperfusion in mice (Bravo et al., 2016), 
however Ara-A and related AC inhibitors are not selective for AC5 over AC6, although 
they show considerable selectivity over other AC isoforms (Braeunig et al., 2013; Brand 
et al., 2013). Therefore, any benefits of Ara-A likely arise from inhibition of both AC 
isoforms. However, this could prove risky, as AC6 deletion increases mortality during 
sustained catecholamine stress (Tang et al., 2013). 
Surprisingly, no polymorphisms that give rise to cardiovascular disease are known 
to occur in ACs (Ikoma et al., 2003). However, mutations in AC5 are linked to familial 
dyskinesia with facial myokymia (FDFM), a disease characterized by uncontrolled 
movement of limb and facial muscles (Chen et al., 2014; Chen et al., 2012). These 
patients may also have a predisposition to congestive heart failure (Chen et al., 2012). 
Two FDFM mutations occur in a newly appreciated region of AC5, a helical domain that 
is present immediately after the transmembrane domain and precedes the catalytic 
cyclase domain (Figure 1). In other nucleotidyl cyclases, this domain forms a tight hairpin 
to induce an active dimeric conformation of the catalytic domains (Vercellino et al., 
2017). Thus, the helical domain may play a role in stability of the catalytic core or direct 
regulation of activity. 
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Figure 1. Topology of AC Isoforms. The structural 
topology of mammalian membranous ACs consists of an N-
terminal (NT) domain followed by a repeating set of 
transmembrane (TM1/2) domains, helical dimerization, and 
cytoplasmic domains. The two cytoplasmic domains (C1 
and C2) make up the catalytic core and the binding site for 
many regulatory proteins. 
 
 
 
 
 
Roles for additional AC isoforms in cardiac function have been largely overlooked. 
AC1 was proposed to function as the calcium-stimulated AC in sinoatrial node that 
modulates the If pacemaker current (Mattick et al., 2007; Younes et al., 2008). However, 
AC1 knockout mice are not reported to have a heart rate defect and RNA sequencing 
detects higher expression of AC1 in right atrium versus sinoatrial node (Vedantham et 
al., 2015). Roles for AC2 and/or AC4 are unknown. Currently, a knockout of AC4 is 
unavailable and AC2 knockout mice display no cardiac phenotype, although RNA for 
AC2 is elevated in pediatric dilated cardiomyopathy subjects (Nakano et al., 2017). 
Cardiac functions for AC9 are discussed below. 
1.2 The AKAP connection: Generating specificity for AC function 
Tissue distribution and regulation provide one mode for how the AC isoforms 
contribute to distinct physiological functions (Dessauer et al., 2017; Sadana and 
Dessauer, 2009). Another mode of signal specificity comes from the formation of AC 
macromolecular complexes through the scaffolding family of A-kinase anchoring 
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proteins (AKAPs). AKAPs not only facilitate cellular localization of ACs but they also 
enhance temporal regulation of cAMP signaling. A number of AKAPs exist in heart 
including, AKAP15/18, AKAP79/150, Yotiao, mAKAP, AKAP-Lbc, and Gravin (Scott et 
al., 2013) (Figure 2). In the heart, the spatial and temporal regulation by AKAPs provides 
an important mechanism to facilitate stress response. The associations of ACs with 
AKAPs facilitate regulation of PKA, downstream effectors and ACs. This was shown in 
the dorsal root ganglion, where the activation of the transient receptor potential vanilloid 
1 (TRPV1) channel by forskolin or prostaglandin E2 is facilitated by AKAP79-AC5-PKA-
TRPV1 complex formation and shifts the response to lower concentrations of forskolin 
by ~100 fold. Disruption of this complex attenuates sensitization of the channel, as 
anchoring of both PKA and AC5 are required to elicit the maximal effect on TRPV1 
current (Efendiev et al., 2013). Anchoring of PKA and ACs to AKAPs can also regulate 
AC activity. Association of AC5/6 with AKAP79/150 creates a negative feedback loop 
where cAMP production is inhibited by PKA phosphorylation of AC5/6 (Bauman et al., 
2006). Although this complex and feedback mechanism was defined in the nervous 
system, modulation of TRPV1 in heart is suggested to influence cardiac response to 
disease and injury (Randhawa and Jaggi, 2017). Fine tuning of the signal is important 
for modulating a number of effectors contributing to physiological function.  
AC localization is assessed primarily through functional roles of associated complex 
members enriched at various cardiomyocyte substructures (Figure 2). Association of 
both AC5 and AC6 with AKAP5 suggests localization at the t-tubule, based upon 
functional association with calcium-induced calcium release (Nichols et al., 2010). 
However, with respect to β adrenergic signaling, AC5 is enriched with β2 adrenergic 
receptors in t-tubules, whereas AC6 localizes outside of the t-tubule (Nikolaev et al., 
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2010; Timofeyev et al., 2013). Disruption of cAMP compartmentalization is potentially 
an underlying mechanism of heart failure (Nikolaev et al., 2010). AC9 association with 
Yotiao and KCNQ1 suggest localization at intercalated discs, the sarcolemma, and t-
tubules (Kurokawa et al., 2004). These AC-AKAP complexes are discussed next.  
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1.2.1 AKAP5 
The AKAP5 family of orthologs are named for their size on SDS-PAGE in different 
species, e.g. human AKAP79, mouse AKAP150, and bovine AKAP75. AKAP79/150 can 
associate with AC 2, 3, 5, 6, 8, and 9 as evaluated in tissue culture models (Bauman et 
al., 2006; Efendiev et al., 2010). In heart, AKAP79 primarily interacts with AC5/6 (Nichols 
et al., 2010). The interaction site is located on the N-terminus of AC and in the second 
and third polybasic domain on AKAP79 (aa 77-153). In cells, AKAP79-scaffolded PKA 
phosphorylates AC5/6 to inhibit cAMP production (Bauman et al., 2006; Efendiev et al., 
2010). This feedback loop allows for precisely timed activation and inactivation of the 
cAMP signal. Although AKAP79-anchored AC5/6 is inhibited by associated PKA, it is 
unclear how AKAP79 regulates AC2 activity in isolated plasma membranes.  
AKAP79/150 has been studied in isolated cardiomyocytes from WT and AKAP150 
knockouts. Deletion of AKAP150 significantly reduced stimulated calcium transients and 
calcium sparks in response to isoproterenol. Additionally, the phosphorylation of the 
ryanodine receptor (RyR) and phospholamban (PLN) were eliminated in cardiomyocytes 
from knockout mice. It was further shown that AKAP150 forms a complex with AC5/6, 
PKA, protein phosphatase type 2 (PP2B or calcineurin), Cav1.2, and caveolin 3 (CAV3). 
This complex is found on t-tubules, while disruption of complex formation upon 
AKAP150 deletion alters CAV3 and AC6 localization (Nichols et al., 2010).  
AKAP150 has additional roles, independent of AC and PKA. AKAP150 localizes 
protein kinase C (PKC) and LTCC to the subsarcolema in atrial myocytes enabling 
regulation of calcium sparklets (Navedo et al., 2008). TRPV4 sparklets are also 
modulated by the AKAP150-PKC complex in a distance dependent manner; where a 
distance less than 200 nM between the TRPV4 and AKAP150-PKC is ideal for proper 
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regulation (Tajada et al., 2017). AKAP150 is also implicated in β1AR recycling. 
Knockdown or knockout of AKAP150 in isolated myocytes inhibits recycling of β1ARs 
back to the membrane after isoproterenol stimulation, but not internalization. Isolated 
AKAP150-/- cardiomyocytes have an enhanced contraction rate in response to 
isoproterenol and an increased cell size at basal and stimulated conditions. Based on 
these results it was postulated that AKAP150 is cardioprotective because the 
hypertrophy phenotype was enhanced in AKAP150-/- (Li et al., 2013b).  
AKAP150 has been examined in a number of pathology models including 
myocardial infarction and pressure overload. AKAP150-/- mice were subjected to 
transverse aortic constriction surgery (TAC) to induce pressure overload, AKAP150 
expression significantly decreased in conjunction with a significant increase in 
hypertrophy, fibrosis, and cell death. Physiologically, deletion of AKAP150 increased left 
ventricular end diastolic size and impaired fractional shortening after TAC compared to 
sham animals. Physiological changes were mirrored by alterations in calcium signaling. 
Phosphorylation of RyR and PLN in addition to calcium transients were impaired in 
response to isoproterenol (Li et al., 2017a). A model of myocardial infarction (MI) was 
also examined in AKAP150-/- mice. Alteration in cardiac signaling after MI is well 
documented. MI causes an increase in NFATc3 activation and associated Kv channel 
down regulation. AKAP150-/- cardiomyocytes displayed impaired NFAT translocation in 
response to phenylephrine, which was dependent on calcineurin activity, preventing 
down regulation of Kv channel currents (Nieves-Cintron et al., 2016). Cardiovascular 
disease is a co-morbidity associated with diabetes (Matheus et al., 2013). Unlike the 
other models, in a model of diabetes mellitus, knockdown of AKAP150 ameliorated 
glucotoxicity induced diastolic dysfunction in mice. In rat cardiomyocytes from diabetic 
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animals or treated with high glucose, AKAP150 expression is enhanced combined with 
increased active PKC at the plasma membrane. This, in turn, promotes activation of 
NFκB and Nox (Zeng et al., 2014), players in the reactive oxygen species pathway that 
underlie diabetes induced cardiovascular injury (Matheus et al., 2013). Thus, while 
AKAP150 may play a cardioprotective role in some pathology models, this is not always 
the case. 
1.2.2 mAKAP (AKAP6) 
Anchored to the nuclear envelope, the cardiac splice variant of muscle AKAP 
(mAKAPβ) interacts with AC5 to facilitate cardiac signaling (Kapiloff et al., 2009; Kapiloff 
et al., 1999). mAKAP is localized to the nuclear envelope through its interaction with 
nesprin (Pare et al., 2005b) while much lower levels of mAKAP are found at the 
sarcoplasmic reticulum (SR) (Ruehr et al., 2004). While mAKAP is intracellularly located 
primarily at the nuclear envelope and AC5 is membrane bound, it is thought that 
localization of AC5 to the t-tubules allows for this interaction due to the close proximity 
of the nucleus and t-tubules at sites within the cardiomyocyte (Escobar et al., 2011; Gao 
et al., 1997). AC5 interacts with mAKAP through a unique binding site on the N-terminus 
(245-340). Similar to AKAP79, PKA binding to the mAKAP complex creates a negative 
feedback loop to inhibit AC5 activity (Kapiloff et al., 2009).  
A number of molecules implicated in hypertrophy are anchored by mAKAP, 
including protein phosphatases 2A and 2B (PP2A/2B), PDE4D3, hypoxia inducible 
factor 1α (HIF1α), phospholipase Cε, myocyte enhancer factor-2 (Vargas et al., 2012), 
and p90 ribosomal S6 kinase 3 (RSK3) (Dodge et al., 2001; Dodge-Kafka et al., 2010; 
Li et al., 2013a; Wong et al., 2008; Zhang et al., 2013). Other proteins are associated 
indirectly with mAKAP complexes, including EPAC1 and the ERK5 and MEK5 mitogen 
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activated protein kinases via interactions with PDE4D3 (Dodge-Kafka et al., 2005). The 
interaction of mAKAP and the RyR at the SR promotes phosphorylation and enhances 
calcium release (Ruehr et al., 2003), while RyR located within the nucleus promote 
hypertrophy as discussed below.   
A role for mAKAP in pathological hypertrophy was first described in mAKAP 
knockdown myocytes (Pare et al., 2005a) and subsequently shown in mAKAP knockout 
mice where knockout mice subjected to TAC had reduced hypertrophy, cell death, and 
did not display TAC inducible gene expression (Kritzer et al., 2014). Further 
characterization of the mAKAP macromolecular complex highlights how multiple 
pathways converge on mAKAP to integrate hypertrophic signaling. The cAMP pathway 
is integrated through AC5-mAKAP-PDE4D3-EPAC binding to utilize and maintain local 
cAMP pools (Dodge et al., 2001; Dodge-Kafka et al., 2010; Dodge-Kafka et al., 2005; 
Kapiloff et al., 2009). Activated calcineurin is recruited to the complex and is required 
for nuclear translocation of NFAT (Li et al., 2010). PLCε binds to a complex containing 
mAKAP, Epac, PKD, and RyR2 contributing to PKD activity, and nuclear calcium levels 
(Zhang et al., 2011; Zhang et al., 2013). 
1.2.3 Yotiao (AKAP9) 
Yotiao is a 250 kDa splice variant of AKAP9 present in heart. Yotiao interacts with 
the alpha subunit (KCNQ1) of the slowly activating delayed rectifier K+ current (IKs), a 
critical component for the late phase repolarization of the cardiac action potential in 
humans (Marx et al., 2002). IKs is made up of four alpha subunits and accessory beta 
subunits, KCNE1. Beta adrenergic control of IKs by PKA phosphorylation of KCNQ1 
increases channel current to shorten the action potential and maintain diastolic intervals 
in response to an increase in heart rate. Mutations in KCNQ1 are associated with long 
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QT syndrome type 1 (LQT1), a potentially lethal hereditary arrhythmia. Not only do 
mutations in the KCNQ1 lead to this disease, but mutations within Yotiao (LQT11) and 
KCNE1 (LQT5) can also give rise to LQT syndrome (Chen et al., 2007; Duggal et al., 
1998). A subset of these mutations in either Yotiao (S1570L) or KCNQ1 (G589D) 
disrupts the KCNQ1-Yotiao interaction, resulting in altered regulation of the IKs channel 
(Chen et al., 2007).  
Yotiao creates a macromolecular complex between KCNQ1 and important 
regulators of KCNQ1 phosphorylation. Yotiao scaffolds both positive (PKA) and negative 
regulators, protein phosphatase 1 (PP1) and phosphodiesterase 4DE3 (PDE4D3), of 
KCNQ1 phosphorylation (Lin et al., 1998; Marx et al., 2002; Terrenoire et al., 2009; 
Westphal et al., 1999). Loss of this scaffold decreases cAMP dependent PKA 
phosphorylation of KCNQ1, eliminates functional response by IKs, and prolongs the 
action potential (Terrenoire et al., 2009). Yotiao is the key to maintaining a tightly 
regulated feedback loop for IKs dependent cardiac repolarization and heart rate. 
Although Yotiao facilitates cardiac repolarization, it cannot overcome channel mutations 
that alter the capacity for phosphorylation. For example, an A341V mutation in KCNQ1 
acts as a dominant negative that reduces basal channel activity and KCNQ1 
phosphorylation with no alteration in Yotiao binding (Heijman et al., 2012). 
Of the AC isoforms that Yotiao scaffolds (AC 1, 2, 3 and 9) (Piggott et al., 2008), 
AC9 is the only one present in cardiomyocytes. Unlike the other AKAPs that interact 
with AC in heart, Yotiao does not scaffold the major cardiac isoforms AC5/6. While 
Yotiao binds to the N-terminus of AC9, there appears to be multiple sites of interaction 
of AC9 on Yotiao, with the primary site located within the first 808 amino acids and a 
second, weaker site that overlaps with the AC2 binding site on Yotiao (amino acids 808-
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956). The interaction of AC9 with Yotiao and KCNQ1 was shown by immunoprecipitation 
of the complex from cells co-expressing all three proteins, a transgenic mouse line with 
cardiac expression of KCNQ1-KCNE1, and from guinea pig hearts, which endogenously 
express the complex. Co-expression of AC9 and Yotiao in CHO cells stably expressing 
KCNQ1-E1 sensitize PKA phosphorylation of KCNQ1 in response to isoproterenol 
compared to AC9 or Yotiao expression alone (Li et al., 2012). Yotiao inhibits AC2 and 
AC3 activity but the mechanism of inhibition is unknown; no inhibition of AC9 activity is 
observed (Piggott et al., 2008). Based on these results we postulate that the AC9-
Yotiao-PKA-KCNQ1 macromolecular complex generates a local pool of cAMP that is 
critical for cardiac repolarization in humans. 
1.3 Newly appreciated AC’s in heart 
1.3.1 AC9 KO phenotype 
An in depth look at the role of AC9 in cardiomyocytes has not been forthcoming for 
a long time. This is likely due to the low level of expression of AC9 in cardiomyocytes, 
the fact that AC5/6 accounts for nearly all of total cAMP production (Sadana and 
Dessauer, 2009), and observations from FA Antoni showing deletion of AC9 through 
conventional targeting was embryonically lethal (Antoni, 2006). The interaction of AC9 
with the Yotiao-IKs complex sparked renewed interest in examining its role in cardiac 
physiology (Li et al., 2012). Meanwhile, the Mutant Mouse Regional Resource Center, 
a NIH funded strain repository, generated a viable AC9 deletion mouse utilizing a gene 
trapping cassette. Examination of this AC9 deletion strain resulted in two distinct 
physiological phenotypes, bradycardia and diastolic dysfunction with preserved ejection 
fraction; no structural abnormalities were observed in AC9 -/- mice using 
echocardiograms (Li et al., 2017b). In addition, Yotiao-anchored AC9 activity is present 
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in the sinoatrial node, supporting a role for AC9 in heart rate. These results are detailed 
in Chapter 4.  
1.3.2 AC9 regulation  
Of the AC isoforms, AC9 is the most divergent in sequence and has been the least 
studied. Expression analysis shows that AC9 is widely expressed in the central nervous 
system, heart, and other tissues (Antoni et al., 1995; Hacker et al., 1998; Paterson et 
al., 2000; Sosunov et al., 2001b). While the regulatory mechanisms of the other isoforms 
have been well studied, studies of AC9 regulation have yielded conflicting results. 
Potential modes of AC9 regulation (Figure 3) include stimulation by Gαs, protein kinase 
C βII (PKCβII) (Liu et al., 2014), or calcium-calmodulin kinase II (CaMKII) (Cumbay and 
Watts, 2005) and inhibition by Gαi/o (Cumbay and Watts, 2004), novel PKC isoforms 
(Cumbay and Watts, 2004), or calcium/calcineurin (CaN) (Hacker et al., 1998).  
 
 
 
 
 
 
 
 
 
 
Figure 3. Modes of AC9 regulation versus AC5/6. (A) Proposed modes of AC9 
regulation based upon whole cells studies. (B) Regulators of AC5/6 activity from whole 
cell and in vitro studies.  
 
Determining the regulatory modalities for various AC isoforms is crucial to understand 
how the individual isoforms function physiologically. Ideally, the regulation of AC9 would 
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be examined in biochemical and tissue culture models, then be confirmed in 
cardiomyocytes, but due to the low levels of expression, examining AC9 regulation will 
prove difficult in this system.      
1.3.2.1 G-protein regulation 
Every membrane bound AC isoform is stimulated by Gαs (Sadana and Dessauer, 
2009). Compared to AC6, AC9 has a right shifted Gαs dose response curve in Sf9 cells, 
showing a reduced sensitivity to Gαs (TA Baldwin, unpublished observations). This 
would potentially impact signaling, where a decreased sensitivity to Gαs reduces 
downstream signaling outputs, making AC9 even more dependent on complex formation 
to facilitate local pools of cAMP. Interestingly, all of the alterations in cardiac physiology 
observed in AC9-/- mice were at basal levels suggesting that AC9 may be more important 
for setting the basal tone in cardiac signaling (Li et al., 2017b). However, in cells AC9 
requires Yotiao anchoring to sensitize the phosphorylation of KCNQ1 in response to 
isoproterenol (Li et al., 2012), emphasizing again the need for complex-dependent 
signaling.  
The original cloning and characterization of human AC9 examined Gαi/o regulation 
of AC9 in HEK293 but did not detect inhibition of AC9 by endogenously expressed 
somatostatin receptors (Hacker et al., 1998). Subsequently, Gαi/o regulation of AC9 was 
reexamined in HEK293 cells upon transient expression of the dopamine receptor (D2L); 
cells treated with a D2L selective agonist, had a significant reduction in AC activity. Thus 
the researchers concluded that Gαi/o may inhibit AC9 (Cumbay and Watts, 2004). It is 
unclear whether the discrepancy between these two studies is due to the type of Gαi/o-
coupled receptor, receptor preference for Gαi versus Gαo, or background activity of 
endogenously expressed AC6. Interestingly, AC9 does not contain the important 
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residues that are required for Gαi  binding and inhibition of AC5 (Dessauer et al., 1998). 
Direct regulation of AC9 by Gαi is described in Chapter 3.  
Gβγ is another common regulator of AC activity, inhibiting AC1, AC3, and AC8 or 
stimulating AC2, AC4, and AC5-7 (Dessauer et al., 2017; Sadana and Dessauer, 2009). 
AC9 regulation by Gβγ had been postulated based on neutrophil chemotaxis studies, 
but never tested in other cells (Liu et al., 2010). Still others have concluded that Gβγ 
does not regulate basal or Gαs-stimulated AC9 activity (Hacker et al., 1998; Premont et 
al., 1996). Despite not having a direct regulatory role, Gβγ binds the N-terminus of AC9 
(Brand et al., 2015; Li et al., 2017b).    
1.3.2.2 Kinase and phosphatase regulation 
Gq regulation of AC9 through CaMKII and PKC was examined in HEK293 cells 
expressing AC9 stably with transient transfection of either the muscarinic receptor M5 or 
the serotonin receptor, 5HT2A. Treatment of cells with the receptor agonists (M5, 
carbachol or 5HT2A, 5HT) potentiated AC9 activity in the presence of isoproterenol; 
expression of the constitutively active Gαq mutant (Q209L) showed similar results. Co-
treatment with receptor agonists and the PKC inhibitor, bisindolylmaleimide, further 
potentiated activity suggesting that PKC acted as an inhibitor of AC9 activity. The 
authors also examined potentiation of AC9 activity by calcium/calmodulin (CaM) kinase 
(CaMK) through the M5 receptor, by treating cells with carbachol in the presence of a 
CaM (W-7) or CaMKII (KN-93) inhibitor; both inhibitors reduced AC9 activity. Thus, Gq 
potentiation of AC activity occurs through activation of CaMKII. However, the authors 
could not determine whether AC9 is directly phosphorylated by these kinases or whether 
regulation was via an indirect mechanism (Cumbay and Watts, 2005).  
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AC9 is also important for neutrophil chemotaxis through activation of AC9 by 
PKCβII. Neutrophils express high levels of AC9 and have also been used to examine 
AC9 regulation. Knockdown of AC9 in a neutrophil cell line was shown to inhibit 
chemotaxis in response to fMLP caused by a decrease in cAMP in extending 
pseudopods (Liu et al., 2010). This mechanism was further dissected to show PKCβII 
knockdown recapitulated the AC9 knockdown phenotype. It was proposed that AC9 
phosphorylation by PKCβII was the mechanism for increased cAMP in neutrophils 
leading to chemotaxis (Liu et al., 2014).  
AC9 was originally cloned from mouse as a calcineurin inhibited isoform (Paterson 
et al., 1995). In HEK293 cells expressing mouse AC9, activity was inhibited by calcium 
in a concentration dependent manner that was restored by increasing treatments with 
the calcineurin inhibitors FK506 or cyclosporin A (Antoni et al., 1995; Paterson et al., 
1995). Subsequent characterizations of human AC9 show conflicting results for 
calcineurin inhibition (Hacker et al., 1998; Paterson et al., 2000). The discrepancy was 
suggested to occur due to differences in variants of AC9 mRNA. Overall, it is unclear 
whether regulator differences reported for AC9 are due to different expression systems, 
species differences, or interaction with cell-specific proteins (including AKAPs). 
1.4 Conclusions  
Multiple distinct AC complexes exist in heart and are important regulators of cardiac 
physiology. While great strides have been made to understand the composition and 
roles of these complexes, there are still many questions left to answer. Pharmacological 
targeting of AC isoforms has been actively pursued, but obtaining isoform specificity is 
difficult, especially for AC5 and AC6. An alternative and widely considered approach is 
targeting specific protein-protein interactions within the cardiac AC complexes. 
20 
 
Targeting components of a complex could provide specificity unlike pan enzyme 
inhibitors, as these complexes frequently contain only a small percentage of the total 
protein in the cell. This was the idea behind disrupting the AC5-mAKAP complex, as 
mAKAP-localized cAMP signaling is involved in cardiac hypertrophy (Kapiloff et al., 
2009). While disruption of this complex was proposed to have a beneficial effect on 
hypertrophy, the opposite effect was observed. In cardiomyocytes disruption of AC5-
mAKAP binding lead to cellular hypertrophy though an increase in cAMP levels. As 
previously discussed AC5 binding to the mAKAP complex creates multiple feedback 
loops to inhibit cAMP production. These data show how important the fine tuning of 
cAMP signaling is and emphasizes the need for extensive studies when designing AKAP 
complex disruptors for therapeutic use. Finally, many ACs interact with up and or 
downstream effectors through AKAP-facilitated interactions. However, there is still the 
possibility that other AC-AKAP complexes have yet to be identified. Moving forward the 
possibility of AC complexes independent of AKAPs should also be considered.   
 The exploration of a role for AC9 in cardiac function has long been forthcoming. 
Based upon its interaction with Yotiao and the growing evidence for macromolecular 
complex dependent regulation of cAMP signaling,  I hypothesize that macromolecular 
complexes facilitate regulation of AC9 that underlies cardiac repolarization. The goal of 
my dissertation work was two-fold, first to determine the direct regulator mechanism 
controlling AC9 enzymatic activity  (Chapter 3) and second to examine the in vivo role 
of AC9 in cardiac function (Chapter 4).   
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Chapter 2           
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 
Figures and text are partially reprinted from Li, Y., T. A. Baldwin, Y. Wang, J. 
Subramaniam, A. G. Carbajal, C. S. Brand, S. R. Cunha, and C. W. Dessauer. 2017. 
Loss of type 9 adenylyl cyclase triggers reduced phosphorylation of Hsp20 and diastolic 
dysfunction. Scientific Reports 7: 5522. This is an open access article distributed under 
the Creative Commons Attribution License (CC BY 4.0) 
http://creativecommons.org/licenses/by/4.0/.  
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2.1 Materials and antibodies.  
All protocols utilizing animals were approved by the Institutional Animal Care and 
Use Committee (IACUC) at The University of Texas Health Science Center at Houston 
in accordance with the Animal Welfare Act and NIH guidelines. 
Drugs used included forskolin (Sigma-Aldrich, St. Louis, MO), isoproterenol 
hydrochloride (Calbiochem, Darmstadt, Germany), DAMGO ([D-Ala2, N-MePhe4, Gly-
ol]-enkephalin) (Bachem, Bubendorf, Switzerland), 49,6-diamidino-2- phenylindole 
phorbol (DAPI), 12-myristate 13-acetate (PMA) and IBMX (3-isobutyl-1-methylxanthine) 
(Sigma-Aldrich, St. Louis, MO).  
Antibodies used for immunoprecipitation and western blotting are shown in Table 
1. Rabbit polyclonal anti-AC9 was generated against human AC9 peptide 
KINPKQLSSNSHPKHPC conjugated to KLH. Affinity-purified antibody showed high 
selectivity for AC9 over AC3, 5, and 6 (data not shown). Antibodies used for Western 
blots were diluted in Tris-buffered saline/Tween 20. 
 
Table 1. Antibodies used for western blotting, immunoprecipitation, and 
immunofluorescence.  
Antibody Supplier/Citation Application 1° Dilution 2° Type  
anti-AC5 (Bavencoffe et al., 
2016) 
WB 1:1000 Mouse  
anti-AC5/6 Santa Cruz 
Biotechnology 
WB 1:1000 Rabbit  
anti-AC9 (N18) Santa Cruz 
Biotechnology 
WB 1:1000 Goat  
anti-AC9 Described above WB 1:1000 Rabbit  
anti-AKAP150 EDM Millipore WB 1:1000 Mouse  
anti-AKAP150 Santa Cruz 
Biotechnology 
IP 2 µg Rabbit 
anti-A.V. Monoclonal 
(JL-8) for GFP/YFP 
Takara Biology WB 
IP 
1:1000 
1:100 
Mouse  
anti-Bves(Popdc1) Santa Cruz 
Biotechnology 
WB 1:1000 Goat 
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anti-cmyc NIH WB 
IP 
1:1000 
1:100 
Mouse 
anti-DYKDDDDK tag Cell Signaling 
Technologies 
WB 
IP 
IF 
1:1500 
1:100 
1:800 
Mouse  
 
Alexa 567 
anit-Flag Sigma Aldrich WB 1:1000 Mouse 
anti-Flag M2 agarose 
affinity gel 
Sigma-Aldrich IP 15 µl 
beads 
--- 
anti-HA Roche WB 1:1000 Mouse 
anti-Hsp20 
(Hsp20-11) 
Santa Cruz 
Biotechnology 
WB 
IP 
1:1000 
2 µg  
Mouse  
Normal mouse or rabbit 
IgG 
Santa Cruz 
Biotechnology 
IP controls   
Alexa Fluor 633 
Phalloidin  
Invitrogen  IF 1:2000 --- 
anti-phospho 
Hsp20 (S16) 
Abcam WB 1:1000 Rabbit  
anti-phospho 
Troponin I (Ser23/24) 
Cell Signaling 
Technologies 
WB 1:1000 Rabbit  
anti-phospho 
Phospholamban (Ser 
16) 
EDM Millipore WB 1:1000 Rabbit  
anti-Phospholamban 
(2D12) 
ThermoFisher WB 1:1000 Mouse  
anti-sodium potassium 
ATPase[EP1845Y] 
Abcam WB 1:10,000 Rabbit  
anti-Troponin I Cell Signaling 
Technologies 
WB 1:1000 Rabbit  
anti-Yotiao (Piggott et al., 
2008) 
WB 
IP 
IF 
1:1000 
2 µg 
1:50 
Rabbit  
 
Alexa 647 
* Western blot (WB), IP (immunoprecipitation), IF (immunofluorescence). Secondary 
antibodies are diluted as follows mouse (1:30,000), rabbit (1:20,000), goat (1:5000), 
Alexa fluorophores (1:500).  
 
2.2 Plasmids and viruses.  
Human AC6, rat AC1, and rat AC2 baculoviruses were amplified and expressed 
in Sf9 cells as previously described (Chen-Goodspeed et al., 2005; Tang and Gilman, 
1991; Tang et al., 1991). Human Flag–tagged AC9 (aa 1-1252; (Hacker et al., 1998)) 
was cloned into the SalI and NotI restriction sites of pFastBacDual to generate a 
baculovirus according to manufacturer’s specifications (Invitrogen). A baculovirus 
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expressing β-galactosidase (β-gal) was used as a control. Eukaryotic expression 
vectors for human Flag-AC9 (full-length, AJ133123; (Paterson et al., 2000)), AC5, Flag-
AC5, AC6, and YFP-AC6 in pcDNA3.1 were previously described (Brand et al., 2015; 
Kapiloff et al., 2009; Li et al., 2012; Sadana et al., 2009). A truncated eukaryotic 
expression vector for human Flag-AC9 (aa 1-1252, AF036927; (Hacker et al., 1998)) 
was also generated to compare the two clones; the truncated form has comparable Gαs-
stimulated activity as full-length when expressed in HEK293 cells (data not shown). The 
HA-tagged mu opioid receptor (µOR) was a generous gift from Dr. Heather Carr 
(UTHealth). The BiFC expression construct for YN-AC5 was previously described 
(Brand et al., 2015). Two types of constructs were designed for AC9. For Myc-AC9-VN 
and HA-AC9-VC, VN and VC were cloned using PCR in frame with the C-terminus of 
full-length AC9, separated by a sequence encoding a 12 and 19 aa linker, respectively. 
Additional AC9-VN and AC9-VC constructs were generated that lacked an N-terminal 
tag and consisted of a C-terminal 7 aa linker (AAAGGGS) followed by VN or VC tags. 
All AC9-VN/VC constructs behaved similarly in assays. Human AC5-VN and AC5-VC 
were cloned by PCR, replacing YFP using KpnI/BamHI restriction sites in AC5-YFP 
(Efendiev et al., 2010). To generate AC6 BiFC clones, the stop codon was deleted and 
a KpnI site was inserted at the end of the coding region. VN and VC were then cloned 
in frame by PCR to the C-terminus of human AC6, separated by a sequence encoding 
a 10 and 9 aa linker, respectively. All clones were verified by DNA sequencing. 
 Myc-Yotiao-pcDNA3 was previously described (Piggott et al., 2008). Myc-tagged 
Hsp20 was purchased from Origene; V5-Hsp20 was a gift from Dr. George Baillie 
(University of Glasgow). A Flag-tag (MDYKDDDDK) plus two residue linker (GA) was 
inserted in frame at the N-terminus of human AC9 using nested PCR primers. The 
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resulting clone was sequenced, and the activity of the tagged protein verified upon 
expression in HEK293 cells and Sf9 cells. YFP-tagged AC9 was similarly created using 
Flag-AC9 pCDNA3 as the starting construct and replacing the Flag-tag with YFP. To 
create a catalytically inactive AC9, aspartate 399 was mutated to alanine using 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). For adenoviral 
expression, GFP and YFP-tagged catalytically inactive (AC9-D399A, AC9d) were 
inserted into the KpnI/XbaI restriction sites of pShuttle-CMV vector. Recombinant 
adenoviruses were produced according to the manufacturer’s instructions (AdEasy 
Adenoviral Vector Systems, Stratagene).  Appropriate clones were selected by RT-PCR 
and sequenced. Note, although AC9d is expressed as YFP-tagged, YFP is typically 
cleaved when expressed by adenoviruses in cardiomyocytes and the full-length YFP-
AC9d is never observed by WB. 
The epidermal growth factor receptor-GFP and lysosomal associated protein 1-
GFP plasmids were generous gifts from Drs. Yong Zhou and Mike Zhu (UTHealth), 
respectively. All of the Popdc-myc tagged constructs full length and truncations were 
generous gifts from Dr. Thomas Brand (Imperial College London) and previously 
described (Andree et al., 2000). Popdc1(or 2)-VN and -VC clones were constructed by 
replacement of the C-terminal myc tag in Popdc-myc with VN or VC by PCR. All clones 
were verified by sequencing 
2.3 Proteins and Sf9 membranes.  
Kinases used included CaMKIIα, a generous gift from Dr. M Neil Waxham 
(UTHealth), and PKCβII (SignalChem, British Columbia, Canada). Myelin basic protein 
(MBP) for control kinase assays is from Invitrogen (Carslbad, CA). Purified calmodulin 
(CaM) was a gift from Dr. John Putkey (UTHealth). Myristoylated Gαo expressed in 
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Escherichia coli was a generous gift from Dr. Greg G. Tall (University of Michigan). Gαo 
was activated with [35S]GTPγS in the absence of Ric-8A (Tall et al., 2003). Gαs-H6 and 
myristoylated Gαi were expressed in Escherichia coli, purified by nickel-NTA and ion 
exchange chromatography, and activated with [35S]GTPγS (Dessauer et al., 1998). Gβ1, 
Gγ2, and H6-tagged Gαi were used for expression and purification of non-tagged Gβ1γ2 
from Sf9 cells (Kozasa and Gilman, 1995). To purify non-tagged Gαi1 and Gαi3 from 
Sf9 cells, proteins were co-expressed with H6-tagged Gβ1 and Gγ2 and purified by 
nickel-NTA chromatography (Kozasa and Gilman, 1995). All G proteins were activated 
by [35S]GTPγS; free GTPγS was subsequently removed by size-exclusion 
chromatography (Dessauer et al., 1998). Baculoviral expression of AC isoforms in Sf9 
cells and subsequent plasma membrane preparation was performed as described 
previously (Chen-Goodspeed et al., 2005).  
2.4 Cell culture, transfection, and membrane preparation.  
COS-7 and human embryonic kidney 293 (HEK293) cells were maintained in 
Dulbecco’s modified Eagle medium containing 10% fetal bovine serum at 37°C with 5% 
CO2; cell lines were authenticated by short tandem repeat profiling (HEK293) or 
mitochondrial cytochrome c oxidase I DNA barcodes (COS-7) by ATCC. The day before 
transfection, the cells were seeded at 2.5 x 106 cells or 1.5 x 106 cells per 10-cm dish 
for HEK293 and COS-7 cells respectively. The cells were transfected with appropriate 
plasmids (10 μg of total DNA per 10-cm plate) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) (Efendiev et al., 2010; Piggott et al., 2008). The transfected cells were 
incubated for 4 to 6 hours before the media was replaced. HEK293 and COS-7 cells 
were harvested 40 to 48 hours after transfection for use in immunoprecipitation (Brand 
et al., 2015; Li et al., 2012) or preparation of cell membranes (Brand et al., 2013). To 
27 
 
prepare lysates for western blotting or immunoprecipitation, transfected cells were 
rinsed in cold phosphate buffered saline (PBS), lysed with buffer (50 mM HEPES (pH 
7.4), 1 mM EDTA, 1 mM MgCl2, 150 mM NaCl, 0.5% C12E9, and protease inhibitors), 
and homogenized with a 23-gauge syringe. Homogenate was cleared of cellular debris 
by centrifugation. An aliquot of total lysates was saved for AC assay or western blot prior 
to immunoprecipitation at 4° C for 1.5 hour with antibody followed by an additional 1.5 
hours with protein A or G sepharose. Immunoprecipitation with Flag agarose was rotated 
at 4° C for 3 hours.  Samples are washed twice in lysis buffer (0.05% C12E9) then 
resuspended in lysis buffer (0 mM NaCl, 0.04% C12E9). 
To prepare cell membranes, cells were rinsed and harvested in cold (PBS), 
pelleted and resuspended in a buffered medium containing 20 mM HEPES pH 7.4, 1 
mM EDTA, 2mM MgCl2, 1 mM DTT, 250 mM sucrose, and protease inhibitors. Cells 
were Dounce homogenized, subjected to centrifugation at 500 x g to pellet nuclei, 
followed by centrifugation at 100,000 x g; membranes were resuspended in buffer 
without protease inhibitors. The resulting samples were immediately used for AC assays 
or frozen for future use.  
Neonatal rat ventricular myocytes (NRVM) were isolated from 1- to 2-day-old 
Sprague-Dawley rat hearts as previously described (Wu et al., 2015). For biochemical 
assays medium was changed 24 hours after plating and 48-72 hrs post isolation NRVMs 
were infected with adenovirus (multiplicity of infection of 50-100) for 50 hrs prior to 
treatments. Experiments were carried out on at least three separate NRVM isolations. 
Isoproterenol was stored and diluted in AT buffer (100 mM ascorbate and 10 mM 
thiourea, pH 7.4). For imaging cardiomyocytes were separated from non-cardiomyocyte 
cells with a Percoll gradient as previously described (Lash and Jones, 1993).  Briefly, 
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cells were resuspended in 1.082 g/mL Percoll. Gradient tubes were prepared in 15 mL 
conicals by adding increasing densities of Percoll (1.05g/mL, 1.062 g/mL, and 1.082 
g/mL). Cardiomyocytes were added to the Percoll gradient tubes and centrifuged at 300 
x g for 30 minutes at room temperature in a swing bucket centrifuge. Cardiomyocytes 
collect at the 1.082 g/mL layer. Cardiomyocytes are collected and washed twice. After 
final wash cell are resuspended in complete media (50% DMEM, 40% HAMS F10, 10% 
FBS + 1% Pen/Strep). Cell were plated on fibronectin coated glass bottom MatTek 
plates (P35G-1.5-14-C, MatTek Corporation, Ashland, MA) at a density of 100,000 
cell/plate and medium was changed 24 hours after plating. 48 hours after plating cells 
are washes to remove debris and media replaced with DMEM + 2% FBS + 1% 
Pen/Strep. Between 72 and 90 hrs post isolation NRVMs were infected with adenovirus 
(multiplicity of infection of 50-100) for 60 hrs prior to fixing and staining. 
2.5 AC9 shRNA and siRNA knockdown.  
AC9 shRNA and control shRNA constructs were a generous gift from Dr. Carole 
Parent (University of Michigan Medical School) and previously described (Liu et al., 
2010). AC9 (SASI_Hs01_00098729 and SASI_Hs01_00098727) and control (SIC001 
siRNA universal negative control #1) siRNAs were purchased from Sigma-Aldrich (St. 
Louis, MO). Control and AC9 shRNA plasmids were packaged into lentiviruses using 
HEK293T cells. COS-7 cells were then transduced with shRNA-encoding lentivirus and 
stable knockdowns were generated by selection with 2 μg/ml puromycin (Liu et al., 
2010). For siRNA knockdown, COS-7 cells were transiently transfected with control 
siRNA (600 pmol) or a mixture of two AC9 siRNAs (300 pmol of each) using 
Lipofectamine 2000, replacing media 4-6 hours post transfection. Cells were harvested 
for membrane assays 60 hours post-transfection. 
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2.6 Adenylyl cyclase membrane assays.  
Membrane assays were performed as described previously (Dessauer, 2002). 
Briefly, membrane (Sf9, HEK293, COS7, or mouse spleen) preparations were incubated 
for 10 minutes at 30°C with an AC mix containing 5 mM MgCl2, 200 µM Mg-ATP, [α-
32P]ATP and purified proteins or drugs. Reactions were terminated with a mix of 2.5% 
SDS, 50 mM ATP, and 1.75 mM cAMP. Each reaction was subjected to column 
chromatography to separate nucleotides and to isolate [32P]cAMP produced during the 
reaction; [3H]cAMP was used to monitor column recovery rates by scintillation counting.  
For kinase-AC assays, kinase reactions preceded measurement of cAMP 
production. Proteins and membranes were diluted as follows: CaMKII (100 ng) was 
diluted in kinase buffer (10 mM HEPES pH 7.4, 200 mM KCl, 0.1% Tween-20, and 1 
mg/ml BSA); Sf9 membranes in 20 mM HEPES pH 7.4 and 2 mM DTT; and calmodulin 
(CaM) in 5 mM MOPS pH 7.0 and 0.01 mg/ml BSA. In a 25 μl reaction, the kinase assay 
was initiated by the addition of 100 ng of CaMKII to 30 μg of Sf9 membranes, 1 μM CaM 
and 10X reaction mix (final concentration:  25 mM HEPES pH 7.4, 10 mM MgCl2, 50 
mM KCl, 2 mM CaCl2, 400 μM DTT, 100 μM ATP). The reaction was incubated on ice 
for 10 minutes, then transferred to 30°C for 5 minutes. The assay of AC activity was 
initiated with 25 μl of AC mix (containing 100 µM Mg-ATP, [α-32P]ATP +/- 100 nM Gαs) 
and incubated for an additional 10 minutes at 30°C. PKCβII reactions were similar in 
design. PKCβII and Sf9 membranes were diluted in 20 mM HEPES pH 7.4 and 2 mM 
DTT. In a 60 μl reaction, PKCβII (5 or 20 nM) was added to Sf9 membranes (15 μg AC2, 
30 μg AC9 or β-gal), 100 μM CaCl2, and 1 μM phorbol 12-myristate 13-acetate (PMA); 
reactions were initiated with activation buffer (final concentration: 20 mM HEPES pH 
7.4, 5 mM MgCl2, and 100 μM ATP) and placed at 30°C for 7 minutes. The subsequent 
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AC assay was initiated with 40 μl of AC mix, (containing 5 mM MgCl2, 100 µM Mg-ATP, 
[α-32P]ATP +/- 100 nM Gαs), and incubated for an additional 7 min at 30°C.  PKCβII and 
CaMKIIα activity were confirmed by measuring [g32P] incorporation into myelin basic 
protein (MBP); control kinase assays substituted [γ-32P]ATP for [α-32P]ATP.   
Preparation of heart extracts and measurement of AC activity were performed as 
previously described (Efendiev et al., 2010; Piggott et al., 2008). AC9 activity in WT 
hearts was estimated from increasing concentrations of the SQ22,536 inhibitor that 
displays >100 fold selectivity for AC5/6 over AC9 (Brand et al., 2013). At X concentration 
of SQ22,536, AC9 activity = (WT-KO)/%AC9 activity remaining at X concentration. The 
% AC9 activity remaining based upon SQ22,536 dose response curves generated with 
AC9 Sf9 membranes (Brand et al., 2013). Averages of 4 experiments, performed in 
duplicate or triplicate, using 10, 30, 100, and 300 μM concentrations of SQ22,536 were 
used for estimates; a 0.08-2.5% difference in activity is observed between WT and 
AC9KO heart membranes. Note, at zero SQ22,536 there is no detectable difference in 
activity. Immunoprecipitation of AKAP or Hsp20 complexes followed by western blotting 
or measurement of associated AC activity was performed as described (Li and 
Dessauer, 2015). AC activity was stimulated with the indicated reagents and cAMP was 
detected by enzyme immunoassay (Assay Designs) or using [γ32P]ATP. 
Throughout the paper, AC activity is primarily displayed as specific activity 
(nmol/min/mg) unless otherwise indicated. Otherwise, results are generally displayed 
after subtracting control background or as fold over basal, as noted in the figure. 
2.7 Live-cell cAMP accumulation monitoring (cADDis and GloSensor).  
COS-7 cells were transiently transfected with an empty vector, µOR, and AC9, 
or AC6; media was changed 4 hours post transfection. After 24 hrs, cells (0.05 x 106 
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cells/ well) were resuspended in DMEM plus 10 % FBS and 6 mM valproic acid, replated 
on a black, poly-l-lysine coated 96 well plate with clear bottom and incubated with 30 μl 
of the BacMam sensor (red upward cADDis; cAMP Difference Detector in situ, Montana 
Molecular, Bozeman, MT), according to manufacturer’s guidelines. Fluorescent 
experiments were conducted 24 hours after addition of sensor with Tecan Infinite 200 
Pro. Red fluorescence was excited at 560 nm, and emitted light was collected at 605 
nM. Prior to fluorescent reads, cell media was replaced with phosphate buffered saline 
(PBS) for 20-30 minutes to acclimate. A baseline read was measured for 7.5 minutes 
prior to addition of drug, fluorescence was then monitored for an additional 15 minutes. 
Isoproterenol and DAMGO were prepared and diluted in AT buffer (0.1 mM ascorbic 
acid and 1 mM thiourea) for cell treatments. The average of the 7.5 minute baseline read 
for each well was subtracted from each point to account for variability between assays. 
Background subtracted fluorescence was averaged over 5-7 minutes post addition of 
drug (12-14 minutes after start of assay).  
 For measurement of basal cAMP accumulation, COS-7 cells were transiently 
transfected with 5 µg of the -20F GloSensor plasmid (Promega, Madison, WI) and with 
AC isoforms or control vectors on a 10 cm plate. 36 hours post transfection, cells were 
replated at a density of 0.05 x 106 cells per well on white, poly-l-lysine coated 96 well 
plates and assayed 4 hours later according to the manufacturer’s protocol. Cells were 
pre-treated with 1 mM IBMX for 10 minutes followed by a 5 minute baseline read. 
Baseline reads were averaged over the 5 minutes.  
2.8 Preparation of spleen membranes and splenocytes.  
Isolation of membranes from wild-type and AC9 knockout mice was performed 
as previously described (Piggott et al., 2008; Efendiev et al., 2010). Briefly, fresh or 
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frozen spleens were washed in ice-cold PBS and quartered. Tissue was resuspended 
and homogenized with a polytron homogenizer followed by dounce homogenizing in a 
buffered medium containing 10 mM HEPES pH 7.4, 5 mM EDTA, 300 mM sucrose, and 
protease inhibitors. The homogenate was centrifuged at 2000 x g to remove cell nuclei, 
the supernatant from the first spin was then centrifuged at 100,000 x g to collect 
membranes. Collected membranes were resuspended in a buffer containing 50 mM 
HEPES pH 7.4, 1 mM EDTA, and 300 mM sucrose. The resulting samples were 
immediately used for AC assays. 
 For preparation of splenocytes, spleens were removed from wild-type and AC9 
knockout mice and placed on ice in PBS. Tissue was homogenized in MACS buffer 
(0.5% BSA and 2 mM EDTA in PBS), filtered through a 40 μm strainer, and cells 
collected by centrifugation (300 x g for 5 minutes). Cells were resuspended in Hybri-Max 
buffer (Sigma-Aldrich, St. Louis, MO) for 4 min to lyse red blood cells. The reaction was 
neutralized with excess MACS buffer, centrifuged and resuspended in MACS buffer for 
counting. Collected splenocytes were then centrifuged and resuspended in RPMI 1640 
media with 25 mM HEPES pH 7.4 and immediately used for cAMP accumulation assays. 
Splenocytes were treated with 1 mM IBMX at 37°C for 20 minutes before addition of 
vehicle or 1 μM isoproterenol. Reactions were stopped by two-fold dilution with 0.2 N 
HCl. Cell particulates were removed by centrifugation and cAMP in the supernatant was 
detected by enzyme immunoassay (Enzo Life Sciences, Farmingdale, NY, catalog # 
ADI-900-066).  
Splenocytes used for profiling were isolated as described above and 
resuspended in 2 mL of freezing media (40% FBS, 10% DMSO, 50% DMEM) and 
aliquoted into four cryovial per sample. Samples were frozen at -80°C for 4 hours then 
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placed in liquid nitrogen. Samples were shipped to Dr. Mark Ormiston’s lab (Queen’s 
University, Ontario, Canada) for profiling. 
2.9 Bimolecular Fluorescence Complementation (BiFC).  
COS-7 cells were transiently transfected as indicated in 12-well plates with VN- 
or VC-tagged AC9, AC5, or AC6. Approximately 40-48 hours post transfection, cells 
were stained with DAPI (49,6-diamidino-2- phenylindole; 10 mg/ml) for 1 hour at 37°C. 
Cells were then scrapped in PBS and transferred to a black 96-well plate with clear, flat 
bottom (Corning Inc, Coring, NY). Venus and DAPI signals were measured with a multi-
well plate reader, Infinite 200 Pro (Tecan, Mannedorf, Switzerland) at room temperature. 
Venus intensity was measured at an excitation wavelength of 506 and emission 
wavelengths of 536-542 nm (2-nm step measurements). DAPI intensity was measured 
at wavelengths of 358 nm (excitation) and 461 nm (emission). Peak signals from 540-
542 nm emissions were averaged and normalized to DAPI signal to account for 
differences in cell number. Background fluorescence from control samples expressing 
pCDNA3 and/or only VN- or VC-tagged protein was subtracted. 
2.11 Generation of AC9 Gene-Targeted Mice.  
The mouse strain used for this research project, B6;129S5-
Adcy9Gt(neo)159Lex/Mmucd, identification number 011682-UCD, was obtained from 
the Mutant Mouse Regional Resource Center, a NIH funded strain repository, and was 
donated to the MMRRC by Lexicon, Inc. The insertion of the gene trap vector was 
generated in strain 129/SvEvBrd-derived embryonic stem cells (International Mouse 
Knockout et al., 2007). The retroviral insertion (5174 bp) occurred in the intron between 
exons 1 and 2. The chimeric mice were bred to C57BL/6J mice to generate F1 
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heterozygous animals. Mice were backcrossed with C57BL/6J mice for 7-9 generations. 
Age matched or wild-type C57BL/6J littermate controls were used as described.  
2.12 Genotyping and RT-PCR. 
Primers used to detect gene trap insertion (WT #1 and KO #3; 494 bp) or WT 
animals (WT #1 and #2; 280 bp) were as follows: KO #3, 
GGCCAAGAACAGATGGAACAG; WT #1, TCCCTAGCCATTCCTAGCAAAGC; WT #2, 
CAGTTCACCTTTTCCATACCCCTAG. Primers used for real-time PCR are from (Landa 
et al., 2005), except AC9. Primer sequences for AC9 are as follows (see Fig 1): AC9-1 
Fwd CGGTCTCCCACAGATGAGAT; AC9-1 Rev, TCTGGGGACAGAAACTGAGG; 
AC9-2 Fwd, CTTTGATAACCTTAAGACTTGC; AC9-2 Rev, 
CAGGAGCTGGAGCGATCATA. Real-time PCR was performed and analyzed as 
described (Bavencoffe et al., 2016), using GAPDH as a control template.  
2.13 Western blotting from heart lysates  
For analysis of PKA phosphorylation in heart, WT and AC9-/- mice were injected 
with saline or isoproterenol (2 µg/g body weight, IP). Animals were sacrificed 4 min later 
and heart tissue was harvested. Cardiac extracts were prepared in the presence of 
phosphatase inhibitors. Equal protein supernatants were subjected to Western blot 
analysis as described in figure legends. 
2.14 Proximity Ligation Assay.  
In situ PLA was performed using a Duolink kit (Sigma-Aldrich, cat. DUO92101) 
following the manufacturer’s protocol. HEK293 cells were cultured on clear bottom 96 
well plates (Greiner Bio-One), transfected with the required plasmids and fixed with 4% 
PFA. After washing the plate 3 times with PBS, the cells were blocked (1% BSA + 
0.075% Triton X100) for 1 h at room temperature and then incubated with primary 
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antibodies overnight. Antibodies included: mouse anti-HSP20 (SC-51955, SantaCruz, 
1:500), mouse anti-GFP (632381, Living colors, 1:500), rabbit anti-GFP (SC-8334, 
SantaCruz, 1:1000), mouse anti-Gβγ (SC-378, SantaCruz, 1:1000), and mouse anti-
cmyc (9E10, NIH, 1:1000). After removal of primary antibodies, the samples were 
incubated with anti-mouse PLUS and anti-rabbit MINUS PLA probes for 1 h at 37 °C. 
Subsequent steps of ligation and elongation were according to the manufacturer’s 
protocol. After the last wash, cells were stained with DAPI (1 μg/ml) and imaged using 
an epifluorescence high content imaging microscope with a 20X objective (Cell Insight 
CX5 High Content Screening platform, ThermoFisher). Data analysis was performed 
using FACS analysis software (FlowJo, USA). To prevent false positives, cells with 
saturating YFP fluorescence or less than 4 positive signals (dots) per cell were not 
considered in the analysis. 
2.15 Echocardiography.  
AC9 knockout and WT mice (3-7 months) were anesthetized in a chamber under 
2.5% isoflurane. After sedation, mice were transferred to a heated platform and fixed in 
the prone position for electrocardiogram recordings and cardiac imaging. Anesthesia 
was administered via a nose cone at 1-1.5% isoflurane during recordings. Cardiac 
imaging was utilized to assess left ventricular (LV) diastolic function and other key 
cardiac parameters. Initial analysis of LV diastolic function was evaluated with pulsed-
wave Doppler (PWD) (20MHz, Doppler Signaling Processing Workstation (DSPW), 
Indus Instruments, Webster, USA) of the mitral valve (MV) inflow (Reddy et al., 2005). 
Key parameters of the mitral valve flow profile including, early (E) and late (A) filling 
velocities, aortic ejection time (AET), isovolumetric relaxation time (IVRT), and 
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isovolumetric contraction time (IVCT) were determined from recordings with DSPW. The 
ratio of the E/A velocities was used to assess changes in LV filling.  
 Further evaluation of LV diastolic function and key cardiac function used high 
resolution ultrasound (40MHz; Vevo 3100, Visual Sonics Inc., Toronto, Canada). All 
analyses were performed in VevoLab (VisualSonic).  LV volume and mass, ejection 
fraction (EF), and fractional shortening (FS) were calculated from recordings of the short 
axis using M-mode imaging. Additional measurements from M-mode imaging included 
the thickness of the LV anterior and posterior wall (LVAW and LVPW) during both 
systole and diastole as well as the velocity of contraction. Diastolic function was 
assessed with both PWD and tissue Doppler imaging (TDI), visualized in apical four-
chamber view. IVCT, IVRT, AET, E and A velocities, myocardial performance index 
(MPI), and E/A ratios were determined from PWD recordings. TDI from the septal side 
of the mitral annulus were used to assess the early (E’) and late (A’) velocities of the 
mitral annulus and the ratio of E’/A’, A’/E’, and MV E/E’. All measurements were 
averaged from 5 cardiac cycles for each parameter. Note, differences in MV E/A and 
E’/A’ ratios are likely underestimates since the A’ and MV A measurements were not 
always possible on WT mice with very fast heart rates where the early wave is dominant; 
this was never an issue with AC9-/- mice.  
2.11 Fluorescence and immunofluorescence imaging  
 HEK293 cells expressing YFP- or CFP- tagged proteins were fixed with 2% PFA 
in PBS for 20 minutes at RT and washed twice with  PBS then mounted on slides. 
Images were acquired 48 hours post transfection with a TE 2000 microscope (Nikon, 
Tokyo, Japan) with a DG4 xenon light source and CoolSNAP camera (Roper Scientific, 
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Trenton, NJ). YFP (excitation 500/20 nm, emission 535/30 nM) and CFP (excitation 
436/20 nm, emission 465/30 nM) images were collected. 
 Approximately 60 hours post infection cardiomyocytes are washed with RT PBS 
and fixed with 2% PFA in PBS at RT for 20 minutes. Cells were permeabilized with 0.1% 
TritionX-100 for 10 minutes blocked with 3% fish oil in PBS for at least an hour at room 
temperature, then incubated with primary antibody diluted in PBS with 0.075% TritonX-
100 and 3% fish oil overnight at 4° C. Primary antibodies used are described in Table 1. 
Images were obtained with a Nikon A1R confocal (Nikon, Melville, NY) with a 40x oil, 
1.49 numerical aperture objective. 
2.12 Statistical Analysis.  
Individual experiments were performed in duplicate or triplicate and repeated a 
minimum of n=3. Experiments are expressed as mean ± standard error of the mean 
(SEM), except where noted. Sample differences were determined with paired or 
unpaired t-tests for comparisons between two groups. Comparisons between single 
groups were determined with a Kruskal-Wallis One Way Analysis of Variance on Ranks 
followed by Dunn’s Method Test. Comparisons between multiple groups were 
determined using two-way analysis of variance (ANOVA followed by Bonferroni’s 
Multiple Comparison Test. Significant p values are expressed as follows: (*) denotes a 
p value of < 0.05, (**) < 0.01, and (***) < 0.001. Analysis was performed with Excel or 
Sigma Plot statistical analysis software. 
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Chapter 3           
Regulatory mechanisms of AC9 enzymatic activity 
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3.1 Introduction 
Of the ten mammalian AC isoforms, AC9 is the most divergent in sequence, and 
it is also the most understudied. Expression analysis shows that AC9 is widely 
expressed in the central nervous system, heart, and other tissues (Berndt et al., 2013; 
Li et al., 2017b; Paterson et al., 2000; Premont et al., 1996; Sosunov et al., 2001a). 
Although AC9 knockout mice were initially reported to be embryonically lethal (Antoni, 
2006), mice lacking AC9 protein expression are viable despite a preweaning subviable 
homozygous phenotype with incomplete penetrance (Li et al., 2017b). Knockdown and 
gene-trapping studies provide clear in vivo roles for AC9 in neutrophil chemotaxis (Liu 
et al., 2010; Liu et al., 2014) and cardiac function (Li et al., 2017b) (discussed in Chapter 
4). Additionally, polymorphism of the ADCY9 gene is associated with risks for asthma, 
and mood and body weight disorders (Berndt et al., 2013; Small et al., 2003).  
While the regulatory mechanisms of many AC isoforms are defined (reviewed 
extensively elsewhere (Dessauer et al., 2017)), studies of AC9 regulation have yielded 
conflicting results. Currently, models of AC9 regulation include stimulation by Gαs, 
protein kinase C βII (PKCβII) (Liu et al., 2014), or calcium-calmodulin kinase II (CaMKII) 
(Cumbay and Watts, 2005) and inhibition by Gαi/o (Cumbay and Watts, 2004), novel 
PKC isoforms (Cumbay and Watts, 2004), or calcium/calcineurin (CaN) (Antoni et al., 
1998). Conversely, the original cloning of human AC9 characterized it as insensitive to 
inhibition by Gαi and CaN (Hacker et al., 1998).  
3.2 Results 
To investigate direct regulatory properties of AC9, Flag-AC9 was expressed in 
Sf9 cells and membranes purified; expression was confirmed via western blotting 
against the FLAG tag and AC9 (Figure 4A). In order to ensure the N-terminal Flag tag 
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did not alter AC9 activity, membranes from HEK293 cells expressing pcDNA3, non-
tagged, and Flag-tagged AC9 were assayed with 300 nM Gαs. No significant difference 
was observed where AC activity fold over control (pcDNA3) were 7.7 +/- 2.0 and 7.7 +/- 
0.8 for AC9 and Flag AC9, respectively. 
3.2.1 AC9 is conditionally stimulated by forskolin.  
AC9 is the only member of the AC isoform group IV, characterized by forskolin 
insensitivity (Hacker et al., 1998; Paterson et al., 1995). Although AC9 is insensitive to 
forskolin stimulation alone, conditional stimulation has not been tested. In vitro AC 
assays were performed with membranes from Sf9 or HEK cells expressing Flag-AC9. 
AC9 activity was examined in the presence of increasing amounts of activated Gαs with 
vehicle (DMSO) or forskolin. β-gal- or pcDNA3-expressing membranes served as 
negative controls for Sf9 and HEK293 membranes, respectively. AC9-containing Sf9 
membranes treated with forskolin in the presence of high concentrations of Gαs were 
weakly, activated compared to membranes treated with Gαs alone (Figure 4B). The 
same weak conditional activation was observed in HEK293 membranes at high 
concentrations of Gαs (Figure 4C). Background AC activity in HEK293 membranes is 
shown (Figure 4D). 
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Figure 4. AC9 is conditionally activated by forskolin. (A) Western blot using α-FLAG 
(top) and goat α-AC9 (bottom) for membranes from Sf9 cells expressing vector control 
(β-gal) or human AC9. Dose-response curves of Gαs stimulation of (B) AC9 and β-gal 
Sf9 membranes in the presence or absence of 50 µM forskolin and (C) membranes from 
HEK293 cells expressing AC9 in the presence or absence of 100 µM forskolin (activity 
from control membranes (D) was subtracted). (D) AC activity of membranes isolated 
from HEK293 cells expressing pcDNA3 (background AC activity). Statistics: Paired t-
test of experimental means comparing the vehicle and forskolin stimulated groups at 
each concentration indicated; n = 3-4 with experiments performed in duplicate; *P < 
0.05, **P<0.01.   
 
3.2.2 AC9 regulation by Gαs and Gβγ subunits.  
It was often noted previously that significantly greater concentrations of Gαs were 
required to activate AC9 in immunoprecipitation-AC assays than to activate other AC 
isoforms (Efendiev et al., 2010; Piggott et al., 2008). To gain further insight into how 
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Gαs-stimulation of AC9 activity compared to other well characterized isoforms, Gαs 
dose-response curves (1 nM – 1 µM) were generated for membranes from Sf9 cells 
expressing AC9, AC6, and β-gal. While dose-response curves for Gαs-activation of AC6 
were comparable to previously published results (EC50 = 100 nM for AC6; (Chen-
Goodspeed et al., 2005)), the Gαs dose response curve for AC9 appears right-shifted 
(EC50 > 300 nM; Figure 5A). For β-gal membranes EC50=175 nM.  
 Gβγ either inhibits (AC 1, 3, 8) or conditionally stimulates (AC 2, 4-7) all other 
membrane bound AC isoforms (Diel et al., 2006; Gao and Gilman, 1991; Gao et al., 
2007; Steiner et al., 2006; Tang and Gilman, 1991; Yoshimura et al., 1996). To 
determine whether AC9 was sensitive to Gβγ, Gαs dose-response curves were 
performed in the presence or absence of 100 nM Gβ1γ2 (Figure 5B). Gβγ had no direct 
effect on AC9 activity at any Gαs concentration. 
 
 
 
 
 
 
 
 
 
Figure 5. AC9 is less sensitive to Gαs compared to AC6 and insensitive to Gβg. 
(A) Dose-response curves of Gαs stimulation of membranes from Sf9 cells expressing 
AC9, AC6, or β-gal. (B) Dose-response curves of Gαs stimulation of Sf9 membranes 
expressing AC9 or β-gal in the presence and absence of 100 nM Gβγ. Statistics: Paired 
t-test of experiment means comparing the vehicle and Gas or Gβg stimulated groups at 
each concentration indicated; n = 3. 
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3.2.3 AC9 is insensitive to direct regulation by Gαi/o in vitro.  
AC9 inhibition by dopamine (D2L)-coupled Gαi/o (Cumbay and Watts, 2004) and 
AC9 insensitivity to somatostatin-coupled Gαi/o (Hacker et al., 1998) have been 
reported. Sequence alignments of the Gαi binding site for AC5 and AC6 with AC9 reveal 
no homology of key Gαi binding residues (Dessauer et al., 1998) (Figure 6A). Because 
the degree of inhibition of AC5 and AC6 by Gαi is dependent on Gαs concentrations 
(Chen-Goodspeed et al., 2005), myristoylated Gαi (purified from E. coli) was tested for 
its ability at 300 nM to inhibit AC9 in the presence of varying concentrations of Gαs 
(Figure 3B) or a fixed concentration of activated Gαs (300 nM) in the presence of 
increasing Gαi (Figure 6C). Regardless of Gαs or Gαi concentrations, no inhibition of 
AC9 was observed, despite significant inhibition of AC6 activity by Gαi in the same 
assays (Figure 6D). Gαi is dually modified in mammalian cells by myristoylation of the 
N-terminal glycine and palmitoylation of the neighboring cysteine residue. Co-
expression of N-myristoyl transferase with Gαi in E. coli results in myristoylated Gαi that 
lacks palmitoylation (Linder et al., 1991), while Sf9 expression gives rise to both 
myristoylation and palmitoylation of Gαi (Linder et al., 1993). To rule out the requirement 
for palmitoylation of Gαi and/or differences in Gi/o family members, Gαi1 (E.coli or Sf9), 
Gαi3 (Sf9), and Gαo (E.coli) were also tested. No inhibition of AC9 activity was observed 
(Figure 6D) when incubated with Gαi1 or Gαi3, despite observed inhibition to AC6 activity 
(Figure 6D). Gαo likewise did not alter basal or Gαs-stimulated AC9 activity, although 
AC1 activity was inhibited by Gαo, as previously shown (Figure 6E; (Taussig et al., 
1994)).  
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Figure 6. AC9 is not directly regulated by Gαi/o in vitro. (A) Structure-based 
alignment of amino acids that correspond to the Gαi binding site in AC5. Based on 
alignment from Dessauer et al., 1998  (B) Gαs dose-response curves for AC9 and β-gal 
Sf9 membranes in the presence and absence of 300 nM Gαi. (C) Gαi dose-response 
curves for AC9 and β-gal Sf9 membranes in the presence of 300 nM Gαs. (D) E. coli 
versus Sf9 purified Gαi isoforms. AC9 Sf9 membranes were stimulated with 300 nM Gαs 
in the presence or absence of 300 nM Gαi1 (E.coli or Sf9) or Gαi3. AC6 membranes with 
50 nM Gαs +/- 300 nM Gαi proteins served as a positive control. (E) Gαo regulation of 
AC9 Sf9 membranes stimulated with 300 nM Gαs; AC1 membranes stimulated with 
100μM Ca2+/ 300 nM CaM with 1 μM Gαo served as a positive control. Statistics: Paired 
t test of experiment means comparing the vehicle and Gαi/o groups at each 
concentration indicated; n = 3-4 with experiments performed in duplicate or triplicate; * 
or # P < 0.05, ** P<0.01.  
 
3.2.4 AC9 is insensitive to CaMKII and PKCβII in vitro.  
CamKII and PKCβII have previously been reported to regulate AC9 in cellular 
assays (Cumbay and Watts, 2005; Liu et al., 2014). To assess whether these kinases 
act directly on AC9, kinase-AC assays were performed. AC9 activity was measured in 
the presence calcium/calmodulin (Ca2+/CaM), non-stimulated CaMKII, or Ca2+/CaM-
activated CaMKII (Figure 7A). CaMKII activity was confirmed by evaluating 
phosphorylation of MBP (Figure 7A, inset). Despite significant CaMKII activity in the 
assays, no significant change in AC9 activity was observed. PKCβII assays were 
performed in a similar manner to CaMKII assays. Gαs-stimulated AC9, AC2, and control 
membranes were assayed in the presence of the phorbol ester, PMA, and activated 
PKCβII (PMA + PKCβII). PKCβII activity was confirmed by an in vitro kinase assay 
measuring MBP phosphorylation (Figure 7B inset). Although PKCβII did not activate 
AC9, it significantly stimulated AC2, as previously reported (Figure 7B; (Zimmermann 
and Taussig, 1996)).  
46 
 
 
Figure 7. Neither CaMKII nor PKCβII directly regulate AC9. (A) AC9 membranes at 
basal or stimulated with 100 nM Gαs in the presence or absence of 200 µM Ca2+/ 4 µM 
calmodulin (Ca2+/CaM), 100 ng CaMKII, or Ca2+/CaM + CaMKII. Inset, 32P labeling of 
MBP by CaMKII, performed in duplicate. (B) AC2, AC9 and β-gal membranes were 
stimulated with 100 nM Gαs in the presence or absence of 1 µM PMA or PMA plus 
purified PKCβII. Inset, 32P labeling of MBP by PKCβII, performed in duplicate. Statistics: 
Paired t test comparing vehicle and kinase groups; n = 3 with experiments performed in 
duplicate, * or # P<0.05, ** or ## P<0.01. 
 
3.2.5 AC9 is not inhibited by Gαi in COS-7 cells.  
 Previous work examining AC9 regulation was performed using whole cells assays in 
HEK293 cells. However, these cells express a significant amount of endogenous Gi/o-
inhibitable AC activity that complicates analysis (Lefkimmiatis et al., 2009). In order to 
test whether Gαi/o inhibition of AC9 could be observed in other cell lines, cAMP 
accumulation assays were performed using the cAMP sensor, cADDis (cAMP 
Difference Detector in situ; (Tewson et al., 2016)) in COS-7 cells. Live cell cAMP 
accumulation was monitored in COS-7 cells transiently transfected with the Gi/o-coupled 
mu opioid receptor (µOR), in the absence or presence of AC6 or AC9. Cells were treated 
with isoproterenol plus or minus the µOR agonist, DAMGO (Figure 8A and 8B). 
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Compared to isoproterenol treatment, the addition of DAMGO did not alter cAMP levels 
in COS-7 cells expressing the µOR alone, consistent with previous reports that COS-7 
cells express largely AC9 (Figure 8C-D) and AC7 (Premont, 1994). As expected, cells 
expressing AC6 showed a significant decrease in isoproterenol-stimulated cAMP 
accumulation when treated with DAMGO.  DAMGO had no effect on isoproterenol-
stimulated cAMP accumulation in cells expressing AC9 (Figure 8A and 8B).  
 
Figure 8. Regulation of endogenous and overexpressed AC9 in COS-7 cells. (A) 
Representative traces of cells expressing the mu opioid receptor (HA-μOR) +/- AC6 or 
AC9 treated with 1 µM isoproterenol (ISO; black squares) +/- 10 μM DAMGO. Arrows 
indicate addition of drugs (ISO/DAMGO). (B) Quantitation of individual cell traces. Data 
were averaged (avg) from 12-14 minute time points of ISO (1 µM) and ISO + 10 μM 
DAMGO. (C) Western blots of COS-7 cell whole cell lysates, confirming expression of 
endogenous or exogenous AC9 (top: rabbit anti-AC9), AC6 (middle), and HA- μOR 
(bottom). (D) Confirmation of endogenous AC9 protein by western blot of membranes 
isolated from COS-7 cells, or cells expressing an AC9 siRNA or control siRNA. AC9 Sf9 
membranes serve as a positive antibody control. The Na-K ATPase served as a loading 
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control for COS-7 cells. Statistics: t test of experimental means comparing ISO and ISO 
+ DAMGO; n = 3-5 with experiments performed in duplicate; *P < 0.05.  
 
3.2.6 AC9 expression alters basal cellular levels of cAMP.  
To examine endogenous AC9 basal activity, we utilized sh and siRNA knockdown 
of AC9 in COS-7 cells. Knockdown of AC9 was confirmed by western blot and AC 
activity assays in membranes isolated from cells expressing a control or AC9 
shRNA/siRNA. Knockdown of AC9 resulted in a 39 +/- 3% reduction in AC9 protein 
(Figure 8D) and a significant reduction in Gαs (39+/-13%) and forskolin (37+/-15%) 
stimulated AC activity (Figure 9A). Overall changes in low basal AC activity are difficult 
to detect in membrane preparations, therefore the cAMP GloSensor was utilized to 
measure basal cAMP levels. The GloSensor plasmid was transiently transfected into 
COS-7 cells expressing control shRNA, AC9 shRNA, or AC9 overexpression plasmid 
(OVE). Knockdown of AC9 significantly reduced basal cAMP levels, whereas 
overexpression of AC9 enhanced basal cAMP levels compared to control shRNA 
(Figure 9B).  
 AC9 is generally expressed at low levels in most tissues (Hacker et al., 1998). 
For example, in heart, AC9 represents less than 3% of total AC activity (Li et al., 2017b). 
Surprisingly, knockout of AC9 significantly reduced AC activity in spleen membranes by 
54 +/- 4% and 47 +/- 9% for Gαs- and forskolin-stimulation, respectively compared to 
wild type mice (Figure 9C). The considerable contribution of AC9 to total spleen AC 
activity presented a unique opportunity to examine endogenous AC9 regulation by Gαi. 
However, wild-type spleen membranes show only modest inhibition by 300 nM Gαi (19 
+/- 2%); the degree of Gαi inhibition was not significantly altered in spleen membranes 
from AC9-/-.  
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 To further reveal contributions from AC9, membranes were treated with the P-
site inhibitor Ara-A which shows preferential inhibition of AC 1, 3, 4, 5, and 6 versus AC9 
(Brand et al., 2013). In membranes treated with 300 nM Ara-A, Gαs-stimulated AC 
activity in AC9-/- membranes was reduced by 70 +/- 9% compared to wild-type, while 
forskolin-stimulated activity was only reduced by 41 +/- 7% (Figure 9C). Although 
differences in basal activity between wild-type and AC9-/- spleen membranes did not 
reach significance, basal whole cell cAMP accumulation in splenocytes isolated from 
AC9-/- compared to wild-type was significantly reduced in cells treated with IBMX (Figure 
9D). Similarly, cAMP accumulation was also reduced in splenocytes from AC9-/- treated 
with IBMX and isoproterenol (Figure 9E), supporting a significant contribution from AC9 
in basal and Gαs-stimulated AC activity in spleen.  
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Figure 9. Basal AC activity is dependent on AC9 in COS-7 cells and splenocytes. 
(A) AC assay of membranes from COS-7 cells stably expressing control or AC9 
shRNA/siRNA stimulated with 400 nM Gαs or 50 µM forskolin. (B) Whole cell basal 
cAMP accumulation was measured in COS7 cells expressing NS shRNA, AC9 shRNA, 
or overexpressing (OVE) AC9 using a GloSensor bioluminescent cAMP reporter. Cells 
were pre-treated with 1 mM IBMX for 10 minutes. (C) AC assay of WT and AC9KO 
spleen membranes stimulated with 400 nM Gαs or 50 µM forskolin in the presence or 
absence of the P-site inhibitor, Ara-A (300 nM). (D-E) Whole cell cAMP accumulation of 
mouse splenocytes isolated from WT and AC9KO mice treated with 1 mM IBMX +/- 1 
μM ISO. Statistics: unpaired t-test of means comparing the indicated groups; n = 3-4 
with experiments performed in duplicate; *P < 0.05, **P<0.01, ***P<0.001.  
 
3.2.7 Subsets of splenocyte cell populations are not altered in AC9 knockout 
The spleen hosts a variety of cells that are either resident to the organ or recruited 
there for innate and adaptive immune processes (Bronte and Pittet, 2013). Given our 
findings that knockout of AC9 decreased of Gas-stimulated cAMP production in isolated 
membranes and reduced basal and isoproterenol stimulated cAMP accumulation in 
splenocytes, we were curious whether AC9 knockout altered the composition of cell 
population present in the spleen. To test this, isolated splenocytes were profiled with 
flow cytometry. Alterations in lymphocyte populations were broken down into B cell, T 
cell (CD4+ or CD8+), natural killer (NK), and natural killer t-cells (NKT) (Figure 10A-H).  
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Figure 10. Gating strategy for profiling of splenocyte cell populations. The gating 
strategy and markers used for sorting subtypes of lymphocytes are described. (A) 
Histogram of cells stained with the membrane impermeant dye 7-aminoactinomyocyin 
D (7-ADD) separates viable and dead cells. (B) Histogram of CD45+ cells to assess 
leukocytes from the viable population. (C) Leukocytes are subjected to forward scatter 
area (FSC-A) and side scatter area (SSC-A) to select for lymphocytes. (D) Lymphocytes 
are evaluated with FSC-A and FSC-H (forward scatter height) to ensure the cells are 
singlets for flow sorting. (E) NK1.1 and CD3 are used to sort lymphocytes into 
subpopulations with natural killer t-cells in quadrant 2 (Q2) and T-cells in quadrant 3 
(Q3) (F) Histogram of B-cell population selected with CD19 (G) CD4 and CD8 antibodies 
are used to separate subpopulations of T-cells (H) Histogram of natural killer t-cells 
marked with NKp46.  
 
The percentage of viable cells, lymphocytes, and subtypes were compared 
between WT and AC9-/- splenocytes (Figure 11A-G). No significant difference was 
detected between subtypes. Although the spread of NK cell percentages historically 
observed in both WT mice from Mark Ostrom’s lab (Queens University) and WT mice 
from our lab was collapsed in AC9-/- mice. It is possible that with more replicates this 
might be significant if the current trends hold.  
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Figure 11. Comparison of splenocyte cell populations isolated from WT and AC9 
knockout mice. (A) Percentage of total viable splenocytes. (B) Percentage of CD45+ 
positive splenocytes. (C-G) Percentage of cell types based on percentage of viable 
CD45+ lymphocytes. (D) WT (historic) is data gathered for percent NK cells from Mark 
Ostrom’s lab (Queen’s University). (G) Total T cells from panel F are separated into 
CD8+ and CD4+ subsets.  
 
3.2.8 AC9 can homo- and heterodimerize.  
To explore why some cell lines show inhibition of overexpressed AC9 by Gi/o-
coupled receptors, but not others, we examined whether AC9 could form heterodimers 
with other AC isoforms, particularly AC5 and AC6 which show strong Gαi-inhibition. 
Homo- and heterodimerization of AC9 was examined in COS-7 cells using Bimolecular 
Fluorescence Complementation (BiFC) with AC isoforms tagged with N- and C-terminal 
halves of the fluorescent protein Venus (VN and VC, respectively). No fluorescence was 
detected upon expression of the individual AC9-VN or AC9-VC constructs. Co-
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expression of AC9-VN and AC9-VC resulted in strong reconstitution of fluorescence, 
indicating significant interaction and homodimerization between AC9 proteins (Ejendal 
et al., 2013). However, only modest homodimerization was detected for AC5 and no 
BiFC interaction between similarly tagged AC6 proteins was observed (Figure 12A).  
 The ability of AC9 to heterodimerize with AC5 and AC6 was also examined by 
BiFC. AC9 interaction with AC5 and AC6 was observed in a configuration dependent 
manner, as not all tested configurations resulted in significant interaction (Figure 7B). 
Significant heterodimerization was detected with AC5/6-VN and AC9-VC constructs. 
However, no significant fluorescence signals were obtained for AC9-VN and N-terminal 
tagged AC5. AC5 and AC6 heterodimerization was not observed in any configuration 
(Figure 12B). AC9-AC5 and AC9-AC6 heterodimerization was confirmed by co-
immunoprecipitation in COS-7 cells (Figure 12C-D). Flag-tagged AC9 +/- non-tagged 
AC5 or AC6 were co-expressed and complexes isolated using Flag-agarose. AC5 and 
AC6 were both detected in immunoprecipitates of Flag-AC9. Neither AC5 nor AC6 were 
pulled-down in the absence of Flag-AC9 expression. Immunoprecipitations of Flag-AC5 
and YFP-AC6 were used as positive controls (Figure 12C and 12D, respectively).  
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Figure 12. AC9 homo- and heterodimers. Quantification of COS7 cells expressing 
BiFC constructs for AC9, AC5, and AC6. The N-terminus (VN) or C-terminus (VC) of 
Venus is fused to the C-terminus of each AC isoform, except where noted. (A) 
Homodimers express both AC-VN and AC-VC. (B) Heterodimer formation utilized AC-
VN (first one listed) with AC-VC from a second isoform. For example, AC5-AC9 
corresponds to co-transfection of AC5-VN and AC9-VC. AC5* is N-terminally tagged. 
(C-D) Cells transiently transfected with (C) Flag AC9 (fAC9) +/- AC5 or (D) fAC9 +/- AC6 
were subjected to immunoprecipitation with Flag agarose and western blotted for Flag, 
AC5, or AC6. As positive controls, Flag-AC5 (fAC5) and YFP-AC6 were 
immunoprecipitated with Flag-agarose or anti-GFP. ∆Indicates non-specific band. 
Statistics: Kruskal-Wallis One Way Analysis of Variance on Ranks followed by Dunn’s 
Method Test comparing AC9 VN to each group indicated; n = 3-5 with experiments 
performed in duplicate; *P < 0.05, **P<0.01, ***P<0.001. #, P<0.001 for AC9/AC5 and 
P=0.01 for AC9/AC6 by t-test compared to AC9VN control; although not significance by 
ANOVA. 
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3.3 Summary 
I have further investigated the mechanism of AC9 regulation by G-proteins and 
kinases, concluding that AC9 is directly regulated by Gαs and conditionally activated by 
forskolin; other modes of proposed regulation occur either indirectly or possibly require 
additional scaffolding proteins to facilitate regulation. I also show that AC9 contributes 
to basal cAMP production because knockdown or genetic elimination of endogenous 
AC9 reduces basal AC activity in COS-7 cells and splenocytes, respectively. 
Importantly, while AC9 is not directly inhibited by Gai/o, it can heterodimerize with Gai/o-
regulated isoforms, AC5 and AC6. 
 
 
  
57 
 
Chapter 4            
Contributions of AC9 to cardiac function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Figures and text are partially reprinted from Li, Y., T. A. Baldwin, Y. Wang, J. 
Subramaniam, A. G. Carbajal, C. S. Brand, S. R. Cunha, and C. W. Dessauer. 2017. 
Loss of type 9 adenylyl cyclase triggers reduced phosphorylation of Hsp20 and diastolic 
dysfunction. Scientific Reports 7: 5522. This is an open access article distributed under 
the Creative Commons Attribution License (CC BY 4.0) 
http://creativecommons.org/licenses/by/4.0/.  
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4.1 Introduction 
We have previously shown that AC9, an understudied largely forskolin-insensitive 
AC isoform, is expressed in adult mouse cardiomyocytes and forms complexes in heart 
with Yotiao, an A-kinase anchoring protein (AKAP) (Li et al., 2012; Piggott et al., 2008). 
AKAPs are important scaffolds that direct the localization, regulation, and integration of 
cAMP-dependent PKA signaling with downstream targets. Dysregulation of AKAP 
organized complexes can lead to cardiac remodeling and development of heart failure 
(Efendiev and Dessauer, 2011; Scott et al., 2013). For example, mAKAP (AKAP6) 
scaffolds AC5 to regulate cardiac stress responses while AKAP79 (AKAP5) scaffolds 
AC5/6 and L-type calcium channels (Dessauer, 2009; Efendiev and Dessauer, 2011). 
Association of AC with AKAP complexes serves to sensitize bound PKA substrates to 
the effects of cAMP, by up to two orders of magnitude (Efendiev et al., 2013; Li et al., 
2012).  
In heart, AC9 is the only AC isoform to associate with Yotiao and the Yotiao-IKs 
channel complex (Li et al., 2012). The IKs channel results from the co-assembly of two 
subunits KCNQ1 and KCNE1. PKA phosphorylation of the anchored KCNQ1 channel 
subunit increases IKs current and shortens the action potential duration to allow sufficient 
diastolic intervals upon increased heart rate. Mutations in either KCNQ1 or Yotiao that 
disrupt their interaction give rise to Long-QT syndrome (LQT1, LQT11; a potentially 
lethal heritable arrhythmia syndrome) (Ackerman and Mohler, 2010). AC9 association 
with Yotiao-KCNQ1 facilitates KCNQ1 phosphorylation by PKA (Li et al., 2012). In 
humans, we suggest that AC9 is important for repolarization of heart. However, since a 
functional IKs is largely absent in adult mice, additional potential roles for AC9 in heart 
are unknown.  
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4.2 Results  
4.2.1 AC9 and Yotiao co-localize in cardiomyocytes.  
 In cardiomyocytes KCNQ1 is detectable at intercalated disks, t-tubules, and 
sarcolemma (Nicolas et al., 2008).  AC9-Yotiao-KCNQ1 complexes have been isolated 
from overexpression and endogenous systems by immunoprecipitation (Li et al., 2012). 
To examine where AC9-Yotiao co-localize Flag-AC9-D399A (Flag-AC9d) and cmyc-
Yotiao I have co-expressed these proteins in neonatal rat cardiomyocytes by adenoviral 
infection (Figure 13). Distinctively, AC9 and Yotiao co-localize at the sarcolemma. AC9 
and Yotiao also appear diffusely within the cardiomyocyte, with occasional co-
localization. It is possible that AC9 and Yotiao also localize to t-tubules and but these 
structures are not present in neonatal cardiomyocytes (Delcarpio et al., 1989).  
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Figure 13. Colocalization of AC9 and Yotiao in rat neonatal cardiomyocytes. 
RNCMs were infected with catalytically inactive Flag AC9-D399A (FLAG AC9d) and 
cmyc-Yotiao adenoviruses for 60 hours. Cells were stained with FLAG (red), Yotiao 
(green), and phalloidin (blue). The composite image is shown in the top left corner 
followed by separate channel images. The scale bars in each image represent 10 µM.   
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4.2.2 Genetic ablation of AC9 results in preweaning subviability.  
AC9 is ubiquitously expressed but physiological roles for AC9 have been largely 
ignored. To investigate the in vivo function of AC9, we utilized a gene-trap strain of AC9 
obtained from the Mutant Mouse Regional Resource Center, a NIH strain repository. 
The AC9-/- strain was created by Lexicon, Inc. using a retroviral insertion between exon 
1 and 2 (Figure 14A). The mouse genotypes were determined by PCR assay (Figure 
14B). AC9 protein is not detectable by western blotting in heart tissue homogenates and 
available antibodies against AC9 do not work well for immunoprecipitation. Therefore, 
to confirm the lack of AC9 protein expression, we probed the Yotiao-AC9 complex which 
forms a tight complex in mouse and guinea pig heart (Li et al., 2012). AC9 protein is 
detectable in immunoprecipitates of Yotiao from wild type (WT) hearts but not AC9-/- 
(Figure 14C). Multiple isoforms of AC were expressed in mouse adult cardiomyocytes, 
including AC 3, 4, 5, 6, and 9 (Li et al., 2012); quantitative PCR of these AC isoforms 
from WT and AC9-/- shows a 35 +/- 9% decrease in AC3 RNA and complete loss of AC9 
but no significant difference in other AC isoforms (Figure 14D).  
 
 
Figure 14. Design and verification of the AC9-/- mouse model. (A) Schematic of AC9 
gene-trap strategy and genotyping primers. Intron distances are not drawn to scale. (B) 
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PCR analysis of genotyping: lanes 1, 2, and 3 represent wild-type (WT), AC9+/- (Het) 
and AC9-/-, respectively. (C) AC9 protein levels were detected by immunoprecipitation 
of pre-immune (PI) or Yotiao complexes from WT and AC9 KO heart extracts followed 
by western blotting (WB) with anti-AC9 antibody. AC9 protein is not detectable in total 
heart extracts by WB (n=5). (D) Real time PCR of cardiac AC isoforms in AC9-/- heart, 
normalized to WT expression levels (n=3; mice 1 month of age). Loss of AC9 mRNA 
was confirmed with primer sets 9-1 and 9-2. Experiments performed by Yan Wang and 
Yong Li, PhD.  
 
Unpublished observations by FA Antoni suggested that conventional targeted 
deletion of AC9 results in early embryonic lethality in mice (Antoni, 2006). Although 
viable, we noted abnormal genotype frequencies for heterozygous mating pairs after 
backcrossing to C57BL/6J (18% WT, 75% Het, 7% KO; n=68, P=0.002). The 
preweaning subviable homozygous phenotype with incomplete penetrance is also 
reported for another Adcy9-/- strain (Adcy9tm1b(EUCOMM)Wtsi) created as part of the 
International Knockout Mouse Consortium (International Mouse Knockout et al., 2007).  
4.2.3 Deletion of AC9 results in loss of Yotiao-associated AC but insignificant 
changes in total AC activity.  
AC9 mRNA and/or protein has previously been detected in both cardiac 
fibroblasts and myocytes (Li et al., 2012; Ostrom et al., 2003), however the degree to 
which AC9 contributes to total AC activity is unknown. Initial measurements of basal and 
Gαs-stimulated AC activity showed no difference between cardiac membranes isolated 
from WT versus AC9-/- mice (Figure 15A). To potentially unmask AC activity stemming 
from AC9, we used a P-site inhibitor that displays >100 fold selectivity for AC5/6 over 
AC9 (Figure 15B) (Brand et al., 2013). No significant difference in total AC activity is 
observed, even at SQ 22,536 concentrations that inhibit 70-90% of AC5/6, but only 20-
30% of AC9 (30-100 µM). From this data, we estimate that AC9 represents less than 
63 
 
3% of total heart AC activity. In order to detect AC9 activity, we examined its association 
with specific AKAP complexes (Li et al., 2012; Piggott et al., 2008). Heart extracts 
subjected to immunoprecipitation of Yotiao show significant AC activity that is brought 
down with Yotiao in the immunoprecipitate; associated activity is lost in AC9-/- (Figure 
15C). This is consistent with our previous findings that AC9 is the only AC isoform 
associated with Yotiao in heart. Although AC9 can also bind AKAP79/150 (Efendiev et 
al., 2010), it does not significantly contribute to the AC activity associated with 
AKAP79/150 in heart (Figure 15D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. AC9 activity and AKAP association in heart. (A, B) Membranes were 
prepared from 6 week WT versus AC9-/- heart. (A) AC activity was measured under basal 
conditions and upon stimulation with 300 nM Gαs or 50 µM forskolin (n=4, performed in 
duplicate or triplicate). (B) AC activity was measured in the presence of increasing 
concentrations of SQ22,536 in the presence of 300 nM Gαs (n = 3, performed in 
duplicate). (C, D) Heart extracts from WT or AC9-/- mice were subjected to 
immunoprecipitation (IP) with pre-immune (control) or anti-Yotiao (C) and control IgG or 
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anti-AKAP5 (D). AKAP-associated AC activity was stimulated with 300 nM Gαs and 
measured (n=3-4). Data are shown as mean +/- SD. A portion of the IP’s from C and D 
were subjected to Western blot analysis for the appropriate AKAP. Note, preliminary 
experiments for A and B were performed by Cameron S. Brand and completed by 
myself. Experiments for Figure C and D were performed by Yong Li, PhD. 
 
4.2.4 Reduced heart rate in the absence of AC9.  
Functional analysis of WT and AC9-/- mice revealed a significant reduction of heart rate 
under isoflurane in both male and female mice for the two age groups examined (Table 
2). Body weight was unchanged in male (21.1 +/- 0.2 versus 21.6 +/- 0.3, 6 months) and 
female mice (15.3 +/- 0.2 versus 15.6 +/- 0.2, 4 months).  
Table 2. Deletion of AC9 gives rise to bradycardia. 
Sex Age (mo) 
Average Heart Rate 
(bpm) p-value 
WT AC9-/- 
Male/Female 1-2 433 +/- 5 
(n=13/6) 
409 +/- 7 
(n=12/6) 
0.008 
Male 5-7 445 +/- 6 
(n=10) 
400 +/- 7 
(n=11) 
0.0002 
 
No structural abnormalities were noted and myocardial performance index (0.9 +/- 0.1 
vs 0.9 +/- 0.1), ejection fraction (53 +/- 3 vs 51 +/- 4) and percent fractional shortening 
(27 +/- 2 vs 26 +/- 3) were all unchanged, as assessed by M mode imaging of mice 3-7 
months (Table 3).  
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Table 3. Cardiac parameters for WT and AC9-/- mice. 
Parameter# WT AC9-/- P value 
Mitral flow doppler    
Peak velocity, E’ (mm/s) 20 +/- 1 15 +/- 1 0.004 
Peak velocity, A’ (mm/s) 16.5 +/- 0.6 16.3 +/- 0.5 n.s. 
Aortic ejection time  
(AET, ms) 51 +/- 2 52 +/- 1 
n.s. 
Isovolumic Relaxation Time (ms) 24 +/- 2 27 +/- 2 n.s. 
Isovolumic Contraction Time (ms) 20 +/- 1 20 +/- 1 n.s. 
Mitral valve A (cm/s) 41 +/- 2 43 +/- 2 n.s. 
Mitral valve E (cm/s) 64 +/- 2 54 +/- 2 0.005 
A’/E’  0.88 +/- 0.05 1.2 +/- 0.1 0.04 
MV E/A 1.57 +/- 0.08 1.27 +/- 0.07 0.01 
MV E/E’ 33 +/- 1 38 +/- 3 n.s., 0.1 
Myocardial Performance Index (MPI) 0.9 +/- 0.1 0.9 +/- 0.1 n.s. 
M-mode Echocardiography    
LV anterior wall, diastole (mm) 0.69 +/- 0.06 0.72 +/- 0.05 n.s. 
LV anterior wall, systole (mm) 0.87 +/- 0.08 1.01 +/- 0.08 n.s. 
LV internal diastolic diameter (mm) 3.6 +/- 0.1 3.6 +/- 0.1 n.s. 
LV internal systolic diameter (mm) 2.6 +/- 0.1 2.7 +/- 0.1 n.s. 
LV posterior diastolic wall (mm) 0.76 +/- 0.08 0.69 +/- 0.04 n.s. 
LV posterior systolic wall (mm) 0.93 +/- 0.07 1.13 +/- 0.07 n.s., 0.06 
EF (%) 53 +/- 3 50 +/- 5 n.s. 
FS (%) 27 +/- 2 26 +/- 3 n.s. 
LV Mass, corrected (mg) 71 +/- 13 70 +/- 7 n.s. 
End diastolic volume (µL) 55 +/- 4 57 +/- 4 n.s. 
End diastolic Volume (µL) 26 +/- 3 28 +/- 3 n.s. 
#, Mean +/- SE is given for male animals 3-7 months. 
 
 
4.2.5 Global PKA phosphorylation is unaltered but Hsp20 phosphorylation is 
decreased in AC9-/-. 
In order to determine if AC9 deletion alters cAMP signaling, we used 
intraperitoneal injection of saline or isoproterenol in WT and AC9-/- mice to evaluate 
changes in phosphorylation of PKA targets. Global changes in PKA phosphorylation at 
baseline or after isoproterenol injection are not detected (Figure 16A), suggesting that 
AC9 does not significantly alter sympathetic responses. However, we detect a large 
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decrease in the basal phosphorylation state of Hsp20 in the absence of beta-adrenergic 
stimulation (Figure 16B). 
To determine if AC9 is present in Hsp20-containing complexes, we used a 
proximity ligation assay (PLA) in HEK293 cells (Figure 16C). The high selectivity of PLA 
relies on double recognition of a protein complex by two oligonucleotide-conjugated 
secondary antibodies. Oligonucleotides in close proximity allows for rolling circle 
amplification that can be visualized (Figure 16C, red dots). YFP-AC9 and Hsp20 display 
a significant signal by PLA as compared to YFP alone. Gβγ binds to the N-terminus of 
AC9 and serves as a positive control (Brand et al., 2015). 
 
 
Figure 16. Basal PKA phosphorylation of Hsp20 is reduced in AC9-/-; AC9 interacts 
with Hsp20. Equal protein supernatants were subjected to WB analysis with (A) anti-p-
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PKA substrate, (B) anti-p-Hsp20. Quantitation of phospho-PKA was normalized to beta-
actin levels (A) while the corresponding total protein was quantitated by WB (n=5-7) and 
the ratio of phosphoprotein to total was quantitated for p-Hsp20 (B) . Graphs for 
quantitation of the ratio of phosphorylated to non-phosphorylated protein are shown to 
the right for each panel. **, P<0.01 t-test on raw intensity values. (C) Proximity ligation 
assay for Hsp20 and Flag-tagged AC9. HEK293 cells were transfected with the 
indicated plasmids. Representative images are shown. PLA signals were quantified by 
high content microscopy (positive cells defined as 4 signals or “dots” per cell; ~2000 
cells imaged per condition). *, P<0.05 t-test, n=3. Data for panels A and B were 
performed by Yong Li, PhD. Panel C was produced in collaboration with Anibal Garza 
Carbajal, PhD.  
 
 AC9 binding to an Hsp20 complex should regulate local cAMP production and 
subsequent Hsp20 phosphorylation. If this is the case, displacing AC9 with a catalytically 
inactive enzyme would lead to reduced local cAMP and Hsp20 phosphorylation. 
Mutation of D399 to alanine deletes a key metal-binding residue in the active site of 
AC9, reducing Gαs-stimulated activity by >90% (Figure 17C). Adenoviral expression of 
AC9d in rat neonatal cardiomyocytes significantly decreased isoproterenol-stimulation 
of Hsp20 (by 77 +/- 6%), as compared to non-infected or GFP-infected cells (Figure 
17A). This is consistent with decreased Hsp20 phosphorylation and Hsp20-associated 
AC activity in AC9-/- heart. Hsp20 is a known PKA target (Beall et al., 1999; Fan et al., 
2005a) and inhibition of PKA activity by H89 blocks isoproterenol-stimulated 
phosphorylation of Hsp20 in rat neonatal cardiomyocytes (Figure 17B). Loss of AC9 
activity in AC9d is confirmed by AC activity assay in Sf9 membranes expressing WT or 
AC9d mutant (Figure 17C). 
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Figure 17. Expression of catalytically inactive AC9 decreases isoproterenol-
stimulated phosphorylation of Hsp20 in rat neonatal cardiac myocytes.  
(A) RNCMs were infected with GFP control or catalytically inactive AC9-D399A (AC9d) 
adenoviruses for 50 hr. Cells were treated with vehicle (AT) or isoproterenol (1 μM) for 
5 min prior to cell lysis. The ratio of p-Hsp20 to total Hsp20 was quantitated by WB.  #,** 
P<0.01 t-test, n=4. (B) Inhibition of PKA abolishes isoproterenol stimulated 
phosphorylation of Hsp20. Rat neonatal cardiomyocytes were pretreated in the absence 
or presence of 10 M of the PKA inhibitor H89 for 10 min followed by vehicle (AT) or 
isoproterenol (1 M) for 5 min. Cells were lysed and subjected to WB analysis for 
phosphorylation of Hsp20 (n=3). (C) Mutation of D399A in AC9 has dramatically reduced 
catalytic activity. Membranes were prepared from Sf9 cells expressing gal, AC9, or 
AC9D399A. AC activity was measured upon stimulation with 300 nM GTPSGs (n=3). 
WB of membrane proteins is shown. 
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4.2.6 Protective role for AC9 against diastolic dysfunction.  
The decrease in baseline Hsp20 phosphorylation in AC9-/- suggests a potential 
loss of the cardioprotective effects of PKA phosphorylated Hsp20 (Edwards et al., 
2012b; Nicolaou et al., 2008; Qian et al., 2009). Therefore,  we measured overall left 
ventricular function using pulsed-wave Doppler echocardiography of early (E) and late 
(A) blood flow velocities through the mitral valve combined with tissue Doppler imaging 
of the mitral valve annulus (E’ and A’ velocity).  Of the four phases of diastolic relaxation, 
isovolumetric relaxation, early ventricular filling, diastasis, and atrial contraction, the 
early filling phase (E wave) appears significantly reduced in AC9-/- mice (Table 3 and 
Figure 18). This was confirmed by tissue Doppler, measuring the early diastolic mitral 
annular velocity (E’) which is preload independent. Trends towards increased filling 
pressures (E/e’) are observed but never reach significance. 
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Figure 18. Cardiac parameters for WT and AC9-/- mice. (A) Pulsed-wave and tissue 
Doppler recordings for female WT and AC9-/- littermates (3 month) showing the relative 
amplitudes of the early ventricular filling (E wave) and the late filling caused by atrial 
contraction (A wave) (ECGs are shown below for each animal). (B) Quantitation of E/A 
ratio at 1-2 (n=10 WT and 8 AC9-/-; males, P=0.0005) or 3-7 months (n=11 WT and 11 
AC9-/-; males and females, P=0.005). (C) Quantitation of mitral valve E wave at 3-7 
months (n=13 WT and 11 AC9-/-, P=0.005). Mean +/- SE. 
4.3 Summary 
AC9 is the most divergent in sequence of the nine mammalian transmembrane 
AC isoforms, is relatively insensitive to forskolin activation and remains the least 
characterized. It was originally cloned as a calcineurin-inhibitable AC isoform (Paterson 
et al., 1995), although it is unclear if calcineurin and other reported cellular regulators 
have direct or indirect mechanisms of action (Dessauer et al., 2017). AC9 mRNA is 
ubiquitously expressed, particularly in the hippocampus (Antoni et al., 1998), and the 
knockout of AC9 was thought to be embryonic lethal (Antoni, 2006). Therefore, 
physiological roles for AC9 have been largely ignored. Despite a preweaning 
subviability, AC9-/- mice show no obvious size or structural abnormalities. However, AC9 
expression is important for human neutrophil chemotaxis (Liu et al., 2010), while ADCY9 
gene polymorphisms are linked to asthma, mood disorders, and body weight (Berndt et 
al., 2013; Small et al., 2003; Toyota et al., 2002). In heart, AC9 mRNA and/or protein 
has been detected in both cardiomyocytes and fibroblasts, although, our estimates using 
P-site inhibitors suggest that AC9 represents less than 3% of total heart AC activity. 
Despite the low levels of AC9, Yotiao-associated AC activity is abolished in the knockout 
while AKAP79-associated AC activity is unchanged. Although AKAP79 can bind to AC9 
in cell culture experiments, AKAP79 scaffolds the highly expressed AC5/6 isoforms in 
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heart (Efendiev et al., 2010; Nichols et al., 2010). The association with Yotiao is 
consistent with a role for AC9 in regulation of IKs channels and potentially long QT 
syndrome, for which mutations of IKs and Yotiao are well known (Ackerman and Mohler, 
2010). 
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Chapter 5           
Adenylyl cyclase and Popdc interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This section details preliminary studies examining AC-Popdc interactions. Most 
results have been replicated two or more times. Any results replicated once are indicated 
in the figure legend. 
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5.1 Introduction 
The bradycardia phenotype observed in AC9-/- mice suggests a role for AC9 in 
the sinoatrial node. Yotiao-AC9 complexes are detectable in the sinoatrial node, the left 
ventricle, and the right atria by immunoprecipitation assays evaluating AC associated 
activity with Yotiao (Li et al., 2017b). In an effort to examine the molecular mechanism 
underlying AC9 involvement in heart rate control we examine the interaction of AC9 with 
a novel cAMP effector involved in heart rate control, Popeye domain containing (Popdc) 
proteins.  
5.1.1 A novel cAMP effector: Popdc 
Protein kinase A (PKA) is the most prominent effector of cAMP; others are briefly 
discussed in the introduction. Popdc proteins represent a novel class of cAMP effectors.  
Although the POPDC genes (Andree et al., 2000; Reese et al., 1999) were discovered 
shortly after EPAC (de  Rooji et al., 1998; Kawasaki et al., 1998), there were only 
recently appreciated as cAMP effectors (Froese et al., 2012; Schindler et al., 2016b). 
The Popdc family consists of Popdc1 (Bves (blood vessel epicardial substrate), Popdc2, 
and Popdc3. Popdc1-3 are highly conserved in vertebrates while most invertebrates 
express two genes; Drosophila uniquely have only one Popdc gene (Brand et al., 2014).   
The Popdc proteins are highly expressed in skeletal muscle and the heart (Andree et 
al., 2000), and in numerous other tissues: lung, gastrointestinal tract, bladder, uterus, 
epithelial cells, and neurons (Andree et al., 2000; Froese and Brand, 2008; Smith and 
Bader, 2006). Popdc1/2 are highly expressed in the sinoatrial and atrioventricular nodes 
(Froese et al., 2012). In cardiac myocytes and tissue, Popdc localizes to the 
sarcolemma, in addition to other structures, including intercalated discs, costameres, t-
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tubules, and caveole (Alcalay et al., 2013). Popdc1 has also been reported to localize 
at the nuclear envelope (Korfali et al., 2012) and nucleoplasm (Brand, 2018).  
Structurally, Popdc proteins consist of three trans-membrane spans, an 
extracellular N-terminal domain with two N-glycosylation sites (Knight et al., 2003), and 
a cytosolic C-terminal domain which contains the Popeye domain responsible for 
binding cAMP (Figure 19A/B) (Andree et al., 2002; Knight et al., 2003). Popdc1 can 
homodimerize (Knight et al., 2003; Vasavada et al., 2004) though interactions in the c-
terminus of the Popeye domain (Kawaguchi et al., 2008) and other unidentified sites 
(Russ et al., 2011).  
 The Popeye domain is highly conserved among the Popdc family. Where the 
homology of the c-terminal portion of the protein is ~92% (Osler et al., 2006). The cAMP 
binding capacity of the Popeye domain was not identified immediately; while the 
predicted secondary structure of the cyclic nucleotide binding domain is similar to that 
of PKA, the sequence of the putative phosphate binding cassette (PBC) is not akin to 
other cAMP effectors (Figure 19A). The DSPE motif  of the PBC is highly conserved 
from worm to humans (Schindler et al., 2016b). Popdc binding affinity to cAMP has an 
IC50 of ~118.4 nM and is 50-fold more selective for cAMP over cGMP which has an IC50 
of ~5.27 μM (Froese et al., 2012).  
Figure 19. Popdc schematics. (A) Linear schematic of Popdc1 and C-terminal 
truncation highlighting the PBC (D200-T218) where residues in red eliminate cAMP 
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binding and in white result in intermediate binding when mutated to alanine. (B) 3-D 
model of the cAMP binding domain (Froese et al., 2012), displayed under license id: 
4458970824151.   
 
5.1.1 Popdc physiological functions 
Popdc1/Bves was discovered by independent groups looking to identify novel 
genes involved in heart development (Andree et al., 2000; Reese et al., 1999).  Since 
then, Popdc proteins have been shown to interact with a number of different proteins 
(overview of select interactions: Table 4) and connected to various roles in cell biology 
and physiology.  
 
Table 4. Popdc protein interactions 
Protein Evidence Function of Pop Reference 
TREK-1* 
GST-PD, Co-
IP, Co-IF, 
FRET, TEVC 
Controls membrane 
trafficking (Froese et al., 2012) 
Caveolin-3 Co-IP, Co-IF Size and number of caveolae  (Alcalay et al., 2013) 
Dystrophin Co-IP, Co-IF Unknown (Schindler et al., 2016a) 
Dysferlin Co-IP, Co-IF Unknown (Schindler et al., 2016a) 
VAMP2,VAMP3 Y2H, GST-PD, Co-IF 
Vesicular transport 
and fusion (Hager et al., 2010) 
NDRG4 
Y2H, GST-
PD, Co-IP, 
Co-IF 
Vesicular trafficking 
(Benesh et al., 2013) 
ZO1 GST-PD, Co-IF, IG-EM 
Epithelial integrity (Osler et al., 2006) 
*Binding modulated by cAMP.  
Abbreviations. GST-PD (glutathione-s-transferase-pull down), Co-IP 
(coimmunoprecipitation), Co-IF (co-immunofluorescence), FRET (Forester resonance 
energy transfer), TEVC (two electrode voltage clamp), Y2H (yeast two hybrid), IG-EM 
(immunogold electron microscopy), VAMP (vesicle-associated membrane protein), 
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NDRG4 (n-myc downstream regulated gene 4), ZO1 (zonula occludens-1). Modified 
from: Schindler, R. F., and T. Brand. 2016. The Popeye domain containing protein 
family-A novel class of cAMP effectors with important functions in multiple tissues. Prog 
Biophys Mol Biol 120: 28-36. Publication is leased under CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
 Genetic deletion of Popdc1 or Popdc2 in mouse leads to an age dependent stress 
induced bradycardia in response to mental stress, exercise, or isoproterenol stimulation. 
While the If current in isolated SAN cells was unaffected by deletion of either Popdc, co-
expression of Popdc1/2 with the two pore potassium channel TREK-1 enhanced 
channel activity and membrane localization of the channel. Popdc1 directly interacts 
with TREK-1; interestingly this interaction is modulated by cAMP. The binding of cAMP 
to Popdc disrupts binding to TREK-1 and reduces TREK-1 plasma membranes 
localization (Froese et al., 2012). 
 Recently, a familial mutation in Popdc1S201F was linked to limb-girdle muscular 
dystrophy (LGMD) and cardiac arrhythmias. Patients develop a severe AV block with 
mild development of skeletal muscle disease. In skeletal muscle biopsies, patients with 
this mutation show significantly reduced Popdc1 and Popdc2 trafficking to the 
membrane. The identified mutation is located in the conserved DSPE motif of the PBC 
in the Popeye domain and alters cAMP binding. Popdc1 binding to cAMP is reduced by 
50% and Popdc dependent enhancement of TREK-1 membrane localization is impaired. 
Homozygous expression of Popdc1S201F in zebrafish recapitulated phenotypes similar 
to those observed in patients (Schindler et al., 2016a). Knockdown of Popdc1 or Popdc2 
in zebrafish shows similar phenotypes (Kirchmaier et al., 2012; Schindler et al., 2016b). 
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5.2 Results 
5.2.1 Interaction of AC and Popdc   
Looking for proteins involved in heart rate control we came across the Popdc 
family. Popdc1/2 are highly expressed in the sinoatrial node, exhibit stress induced 
bradycardia, and are novel cAMP effectors. Additionally, AC9 and AC3 have been linked 
with Popdc2 in a large-scale human interactome screen (Huttlin et al., 2015). To test 
whether AC and Popdc interacted Flag tagged AC9 (or non-tagged AC3) was co-
expressed +/- Popdc1-myc or Podpc2-myc in HEK293 cells. Complexes were isolated 
via the myc tag and associated AC activity was measured (Figure 20A). From the activity 
assays it appeared that AC9 interacted with Popdc1 but not Popdc2, while AC3 did not 
interact with either isoform. However, when immunoprecipitations were evaluated via 
western blot, significant amounts of AC3 (Figure 20D) and AC9 protein (20C) were 
detected in both Popdc1 and Popdc2 pull downs. It appears that while Popdc1/2 can 
pulldown AC3 there is dramatic inhibition of AC3 associated activity. While Popdc1 pulls 
down AC9 and maintains associated activity, Popdc2 pulls down AC9 and inhibits 
activity. In these assays, that have been used to identify numerous AC-AKAP 
interactions, a lack of associated activity typically corresponds to a lack of interaction 
(Efendiev et al., 2010; Kapiloff et al., 2009; Li et al., 2012; Piggott et al., 2008). A 
corresponding inhibition of AC activity was observed in total lysates upon co-expression 
of AC9 with Popdc2 or AC3 with Popdc1/2 (Figure 20B).     
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Figure 20. Popdc interacts with AC3 and AC9. (A) HEK293 cells expressing Flag AC9 
or AC3 +/- myc tagged Popdc 1 or 2. Cell lysates were subjected to immunoprecipitation 
of myc and assayed for AC activity with 300 nM Gas-GTPγS. (B) Total AC activity of 
cell lysates. (C-D) Western blot of lysates and IPs from IP-AC assay, blotting for myc 
(Popdc), FLAG (AC9), or AC3. Membranes isolated from Sf9 cells expressing Flag AC9 
or AC3 serve as positive controls. * indicates a non-specific or alternative form of AC9 
only present in lysates. Note, Popdc protein runs as multiple bands (48-65 kDa; 
confirmed in KO) with altered sizes/patterns in different tissues likely due to changes in 
glycosylation patterns (Schindler et al., 2016a). 
 
 
AC9 and Popdc1/2 interactions were confirmed by performing reverse 
immunoprecipitations. Popdc1/2-myc +/- Flag AC9 were expressed in HEK293 cells and 
complexes were isolated with Flag-agarose. Popdc1 and Popdc2 were both detected in 
immunoprecipitates of Flag-AC9 (Figure 21).  
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Figure 21. AC9 pulls down Popdc1/2. Lysates from HEK293 cells expressing Popdc 
1 or 2 +/- FLAG AC9 were subjected to immunoprecipitation with FLAG-agarose and 
western blotted for top: myc (Popdc) or bottom: Flag (AC9).  
 
AC9-Popdc1/2 interactions are also detectable in COS-7 cells in BiFC 
experiments (Figure 22). No fluorescence was detected upon expression of the 
individual Popdc1-VN or AC9-VN constructs. Co-expression of AC9-VN and Popdc1-
VC or Popdc2-VC resulted in variable reconstitution of fluorescence. Expression of AC9-
VN with AC9-VC serves as a positive control. Interaction of AC9 and Popdc1 although 
variable showed significant interaction.  
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Figure 22. AC9-Popdc1 interaction. Quantification of COS7 cells expressing BiFC 
constructs for AC9, Popdc1, and Popdc2. The N-terminus (VN) or C-terminus (VC) of 
Venus is fused to the C-terminus of each protein. The first protein listed is tagged with 
VN and the second VC. Experiments performed by Simi Rahman.  
 
 
The list of Popdc protein interactions is quite numerous (Schindler and Brand, 
2016). To ensure that Popdc-AC interactions were specific and Popdc did not interact 
with any membrane bound protein we tested whether Popdc1 would pulldown other 
membrane bound proteins including the epidermal growth factor receptor (EGFR) which 
localizes to the plasma membrane or lysosomal associated membrane protein 1 
(LAMP1) which localizes to the lysosomal membrane. Popdc1 was co-expressed with 
or without YFP-AC9, EGFR-GFP, or LAMP1-GFP. Complexes were 
immunoprecipitated with cmyc and western blotted (Figure 23). Only AC9 was present 
in Popdc1 pull downs.  
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Figure 23. Popdc-AC9 interactions are specific. Immunoprecipitation of myc from 
HEK293 cells expressing myc-Popdc1 +/- YFP-AC9, EGFR-GFP, or LAMP1-GFP. 
Lysates and IPs were subjected to western blotting for GFP (top) and myc (bottom), 
n=1. 
 
 Of the proteins that interact with Popdc, binding to TREK-1 is modulated by cAMP 
binding (Froese et al., 2012). Popdc bound to cAMP prevents interaction with TREK-1 
and reduces channel current by reducing channel expression on the membrane. To test 
whether Popdc binding to cAMP influenced AC interaction with Popdc or associated 
activity, cells were transfected with AC9 +/- Popdc1 or Popdc2 and treated with vehicle 
(DMSO) or forskolin for 30 minutes before lysis. Cells treated with forskolin were lysed 
in the presence of 1 µM exogenous cAMP. Complexes were immunoprecipitated with 
myc then associated AC activity and protein was measured. While cAMP does not alter 
AC9-Popdc binding, inhibition of AC associated activity is increased by both Popdc1 and 
Podc2 in lysates and IP. AC9 activity in lysates is not altered with 1 μM exogenous 
cAMP (Figure 24 A/B).  
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Figure 24. Popdc binding to cAMP inhibits AC9 activity. (A) AC activity and western 
blots of IP-AC assays of HEK293 cells expressing Flag AC9 +/- Popdc 1 or 2. Cells were 
stimulated for 30 minutes with forskolin prior to IP with 1 µM cAMP. (B) Total lysate AC 
activity and protein levels before immunoprecipitation. 
 To begin to narrow down the site of AC-Popdc interaction, a c-terminal truncation 
mutant was tested that deletes most of the  Popeye domain, Popdc1D172 (Figure 19A). 
HEK293 cells were transfected with AC9 +/- WT Popdc1-myc or Popdc1D172-myc and 
complexes were isolated. AC activity associated with Popdc1 was reduced in complexes 
pulled down with Popdc1D172-myc, with no altered protein interaction (Figure 25 A/B). 
In lysates AC9 activity was inhibited to a similar extent with co-expression of either WT 
or Popdc1D172 (Figure 25 C). AC9 interaction with Popdc1D172 was confirmed in whole 
cells using proximity ligation assay (PLA). A vector control (pcDNA3) and Popdc-myc 
expressed with myristoylated YFP were used as negative controls and show no PLA 
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signal. Whereas a positive PLA signal is observed by expression of YFP-AC9 with 
Popdc1 WT or D172 (Figure 25 D).     
  
Figure 25. AC9 interacts with Popdc1D172. (A) IP-AC assay of Flag AC9 +/- Popdc1 
or Popc1D172 truncation mutant (PopD). (B) AC activity from lysates of IP-AC assay. 
(C) Western blot of lysates and IP-AC assay. (D) Proximity ligation assay using anit-
YFP and anti-myc (Popdc) in HEK-293 cells. PLA signal (red), DAPI (blue).  
 
 Popdc regulation of TREK-1 membrane localization and activity is likely the 
underlying cause of the stressed induced bradycardia observed in Popdc1 or Popdc2 
knockout mice (Froese et al., 2012). The importance of TREK for maintaining normal 
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SAN excitability was recently shown, a cardiac specific knockout of TREK-1 exhibited 
bradycardia and reduced background potassium current (Unudurthi et al., 2016).   To 
determine whether AC9 could associate with the TREK-1-Popdc complex, Popdc1 was 
immunoprecipitated from cells co-expressing with TREK-1 and AC5 or AC9. Popdc1 
brought down both AC9 and AC5 in addition to TREK-1 (Figure 26 A). Neither AC5/9 or 
TREK-1 were observed in immunoprecipitates when Popdc1 was not expressed. 
Similarly, IP of TREK-1 brings down AC9 and endogenous Popdc1, while 
overexpression of Popdc enhances AC9 binding with TREK-1 (Figure 26 B). Compared 
to Popdc1, neither endogenous or exogenous AKAP79 interacts well with TREK-1; 
although TREK-1 has been shown to interact with AKAP79 (Sandoz et al., 2006). Co-
localization of Popdc-TREK-1 and AC9-TREK-1 is observed in HEK293 cells (Figure 26 
C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. TREK-Popdc1-AC9 complex. (A) Expression of AC9 or AC5 +/- TREK-1 
and Popdc1. IP/WB with myc-Popdc1. (B) IP of GFP-TREK-1 pulls down AC9 and 
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endogenous or overexpressed Popdc1, but not AKAP79. (C) Co-localization of TREK-
CFP and YFP- Popdc (left) or TREK-CFP and YFP-AC9 (right), n=1. 
 
5.3 Summary  
 While AKAPs are the best studied AC scaffolds, in our efforts to understand the 
molecular mechanism of bradycardia in AC9-/- mice we have identified a novel AC 
scaffold and regulator, Popdc. To date this is the first description of AC-Popdc 
interaction. We show that Popdc1 and Popdc2 interact with both AC3 and AC9 by 
immunoprecipitation, PLA, and BiFC. Dependent on isoform (both Popdc and AC), 
interaction of Popdc with AC can potently inhibit AC activity. This occurs in a cAMP 
dependent manner, where IP of the Popdc1-AC9 complex has reduced AC activity when 
exogenous cAMP was included in the lysis and IP steps. AC9 interacts with a truncation 
mutant of Popdc1 that lacks most of the Popeye domain and the C-terminus. This 
suggests that the interaction of Popdc1 with AC9 occurs via the transmembrane 
domains or initial portion of the Popeye domain; two distinct binding sites may also be 
possible.  
The underlying mechanism of Popdc heart rate regulation is thought to be driven 
by interaction with TREK-1. Both AC9 and AC5 can associate with a Popdc1-TREK 
complex when exogenously expressed in HEK293 cells and immunoprecipitated. Co-
localization of AC9 and TREK at the plasma membrane can also be detected in HEK293 
cells.   
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Chapter 6           
Concluding remarks and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
6.1 Summary of conclusions  
Regulation of the enzyme adenylyl cyclase occurs on multiple levels. Broadly, 
physiological contributions of AC are regulated by tissue distribution. Specifically, 
enzymatic activity is regulated by heterotrimeric G-proteins, kinases, phosphatases, and 
calcium. Scaffolds add an additional layer of regulation, contributing to localization, 
indirect or direct regulation of enzymatic activity, and subsequent activation of 
downstream cAMP effectors. Although studies from my laboratory and others have 
provided insights into the possible physiological roles of AC9 (Berndt et al., 2013; Li et 
al., 2017b; Liu et al., 2010; Mahadeo et al., 2007; Small et al., 2003; Toyota et al., 2002), 
further elucidation of AC9 regulation is essential for a comprehensive understanding of 
how this enzyme functions and is controlled in vivo.  
I first evaluated the direct regulation of AC9, showing that many proposed 
regulators work indirectly suggesting an alternative mechanism of AC 
heterodimerization to explain previous findings. Next I examined roles for AC9 in cardiac 
physiology and signaling are examined. Genetic deletion of AC9 in mice reduces total 
cardiac cAMP by ~3% yet it results in two cardiac phenotypes; diastolic dysfunction and 
bradycardia. These phenotypes likely arise from distinct mechanisms dependent on 
unique AC9-containing macromolecular complexes. Lastly, I examined a novel AC 
interacting partner, Popdc. This interaction represents a possible mechanism for the 
AC9 bradycardia phenotype. My findings also suggest that Popdc is a novel scaffold 
and negative regulator of AC activity.  
6.2 AC9 regulation 
Although no splice variants of AC9 are reported, proteolytic alterations of AC9 
give rise to two main forms observed in both rodent and human heart (Palvolgyi et al., 
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2018). The extended C-terminus of the larger form (~170 kDa) is reported to auto-inhibit 
AC9; this is lacking in the smaller form (~130 kDa) (Palvolgyi et al., 2018). To complicate 
regulation analysis, two main human clones have been utilized previously in studies of 
AC9 regulation. A truncated form of AC9 that lacks the last 75 aa of C2b domain (aa 1-
1252; predicted molecular mass 144.2 kDa) was used to examine Gαi/o, CaMKII, and 
nPKC regulation (Cumbay and Watts, 2004; Cumbay and Watts, 2005; Hacker et al., 
1998). Others have examined full-length AC9 (aa 1-1327; predicted molecular mass 
147.7 kDa) for calcineurin and PKCβII regulation (Antoni et al., 1998; Liu et al., 2014; 
Paterson et al., 2000). My study utilized both forms: the truncated version for Sf9 
expression and full-length for mammalian cell expression, however I did not observe a 
reduction in Gαs-stimulated activity for the full-length when expressed in HEK293 cells 
(data not shown).       
There are a number of potential reasons for the conflicting reports surrounding 
AC9 regulation. Previous studies lack consistency in cell type, using a variety of cell 
types from HEK293 or neutrophil cell lines, to isolated mouse neutrophils. In particular 
the conflict surrounding Gαi regulation may be due to the use of different Gαi/o coupled 
receptors where use of the SST2 receptor showed no inhibition of AC9 activity (Hacker 
et al., 1998) while use of the D2L receptor showed AC9 inhibition (Cumbay and Watts, 
2004). Adding to this, HEK293 cells endogenously express AC isoforms that are 
inhibited by Gαi, AC1,5, and 6 (Lefkimmiatis et al., 2009). These reasons prompted the 
evaluation of AC9 regulation using isolated membrane and purified proteins.  
6.2.1 Conditional regulation of AC9 by forskolin  
The plant diterpene, forskolin, is a potent activator of all the membrane bound 
ACs except AC9. Forskolin is regularly used as an experimental tool to examine 
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physiological and pathophysiological roles of AC. Forskolin acts by stabilizing the 
interaction of the C1 and C2 domains of AC by an order of magnitude resulting in a 60-
fold increase of Vmax (Sunahara et al., 1997) without altering the Km of ATP (Dessauer 
et al., 1997).  Mammalian AC9 has long been categorized as the only membrane-bound 
AC isoform that is forskolin insensitive (Hacker et al., 1998; Premont et al., 1996). 
Interestingly the Drosophila homolog of AC9 is sensitive to forskolin activation 
(Iourgenko et al., 1997). A point mutation in the C2 domain of mouse AC9, 9C2-Y1082L, 
restores  sensitivity to forskolin at suboptimal concentrations of Gαs. Mutation of the 
corresponding residue in the C2 domain of AC2, 2C2-L912Y, eliminates forskolin 
activation (Yan et al., 1998).  While forskolin is unable to stimulate basal human AC9 
activity (Hacker et al., 1998), it can weakly activate AC9 in the presence of Gαs. 
Synergistic activation by Gαs, observed with other isoforms, likely promotes forskolin 
binding, despite alterations in the forskolin binding pocket of AC9 (Yan et al., 1998). The 
conditional activation of AC9 by forskolin is modest at best. This would discourage the 
pan use of forskolin alone as significant contributions by AC9 could be overlooked. 
Although this may be true, homo- and heterodimerization of AC9 (discussed below) 
could complicate the simplicity of this idea.  
6.2.2 AC9 is not directly regulated by most G-proteins or kinases.  
Like all other transmembrane AC isoforms, AC9 is directly activated by Gαs. 
However, the Gαs dose-response curve for AC9 is right shifted in comparison with other 
ACs (Chen-Goodspeed et al., 2005; Dessauer et al., 2017). Gαs interacts with the loop 
between the α1’ and α2’ helices of the C2 domain (Tesmer et al., 1997) (Figure 27). A 
possible explanation for the observed shift in Gαs dose-response curve is the shorter 
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loop between these two helices, which is two amino acids shorter in human AC9 
compared to human or rat AC2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Complex of 5C1:2C2 with forskolin, ATP, and GTPgS-Gas. AC5 C1 
domain, blue; AC2 C2 domain, white; Gas, red. Model based on the crystal structure 
PDB 1CJU (Tesmer et al., 1999; Tesmer et al., 1997). NGL viewer: web-based 
molecular graphics for large complexes. Bioinformatics 
dio:10.1093/bioinformatics/bty419), and RCSB PDB. 
 
Predicted N-glycosylation sites are conserved among the AC isoforms on the fifth 
and/or sixth extracellular loops (Wu et al., 2001). The functional relevance of 
glycosylation varies depending on isoform. Preventing glycosylation of AC6 results in 
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reduced inhibition by PKC and Gαi (Wu et al., 2001) while prevention of AC9 
glycosylation left shifts Gαs-stimulation (Cumbay and Watts, 2004). At first glance, this 
suggests glycosylation as a mechanism for reduced Gαs sensitivity. This is unlikely as 
a requirement for increased Gαs has been observed in multiple systems where AC9 
would be glycosylated, e.g. in Sf9 or HEK293 cells (Efendiev et al., 2010; Piggott et al., 
2008).   
 Gβγ either conditionally stimulates (AC 2, 4-6, 7) or inhibits (AC 1, 3, 8) all other 
AC isoforms reviewed in (Dessauer et al., 2017; Sadana and Dessauer, 2009). Gbg 
binds the N-termini of several AC isoforms (AC1-3, 5-6, and 9). Mutation of the Gbg 
hotspot alters regulation of AC1, 2, 5, and AC6 and disrupts binding to AC1-3, 5-6, 8, 
and 9 (Brand et al., 2015). Several labs, including this study, have shown that Gβγ does 
not directly regulate AC9 (Hacker et al., 1998; Premont et al., 1996), although it may 
indirectly activate AC9 in neutrophils (Liu et al., 2010). Despite not directly regulating 
AC9, Gβγ binds to the N-terminus of AC9 (Brand et al., 2015), suggesting that the N-
termini of AC9 may serve as scaffolding site for heterotrimeric G proteins, as previously 
shown for AC5 (Sadana et al., 2009). 
 The lack of direct regulation of AC9 by Gαi/o, although contradictory with some 
whole cell studies, is not entirely surprising. AC9 has little homology with the Gαi binding 
site on AC5; only one of six residues required for AC5 inhibition is conserved in AC9 
(Dessauer et al., 1998). Moreover, Gi/o-coupled chemokine receptors enhance cAMP 
production in neutrophils (Mahadeo et al., 2007). In this system, Gi-coupled receptors 
promote Gβγ activation of mTOR and subsequently PKCβII, ultimately stimulating cAMP 
production by AC9. Direct inhibition of AC9 by Gαi in this system would be 
counterproductive to the indirect stimulation of AC9 by Gβγ (Liu et al., 2014; Surve et 
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al., 2016). Rather, Gαi in neutrophils appears to act on other effectors in a cAMP 
independent manner, targeting RAP1GAPII (Mochizuki et al., 1999) to regulate 
neutrophil adhesion (To and Smrcka, 2018).  
 AC9 was originally cloned as a calcineurin (PP2B) inhibited isoform (Paterson et 
al., 2000), implying that phosphorylation is an important aspect of AC9 regulation. AC9 
contains two predicted PKC sites (T309 and S374; Scansite 4.0, MIT), which are located 
at the base of TM6 or within an 18 aa insert unique to AC9, prior to the catalytic core. 
While our in vitro results do not support a direct role for PKCβII or CaMKII regulation of 
AC9, it is possible that a scaffolding protein, absent from our in vitro studies, is required 
to facilitate AC9 phosphorylation (Dessauer, 2009). Alternatively, another PKC isoform 
could regulate AC9 as other reports of PKC regulation conclude AC9 is inhibited by a 
novel PKC isoform (Cumbay and Watts, 2004). It is also possible that PKCβII and 
CaMKII phosphorylate a yet unidentified upstream regulator of AC9.  
6.2.3 Regulation of basal cAMP levels.  
Examining basal levels of AC activity is difficult; not only are basal levels 
frequently used to normalize data, but they can be error prone, occurring at the lower 
limit of detection for some techniques. A few reports have noted differences in AC basal 
activities, specifically AC1 and AC3 in olfaction (Bakalyar and Reed, 1990) and AC2 and 
AC6 (Pieroni et al., 1995), suggesting that basal levels of cAMP production are important 
aspects of their physiological roles. In support of this concept, the most notable effects 
of AC9 knockout on cardiac function occurred at baseline, where mice had reduced 
heart rates, diastolic dysfunction, and reduced phosphorylation of the small heat shock 
protein 20 (Li et al., 2017b). Alterations in basal AC activity with either knockdown or 
knockout of AC9 in COS-7 cells and splenocytes was revealed under 
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phosphodiesterase inhibition, a similar effect was recently reported in HEK293 cells 
(Palvolgyi et al., 2018). Comparison of the Drosophila homolog of AC9 (DAC9) and 
mouse AC9 also support these findings. Expression of mouse AC9 has enhanced basal 
activity, which is diminished in cells expressing DAC9. While activation by Gαs is 
enhanced in DAC9 compared to AC9 (Iourgenko et al., 1997). It should be noted that 
there is a nuanced difference between these studies. Some of findings show that AC9 
contributes to basal cAMP while others show a role in basal AC activity when 
phosphodiesterase inhibitors are used. Taking into account the reported contributions 
of AC9 to basal cAMP levels and decreased sensitivity to Gαs, the physiologically 
significance of AC9 might be dependent on the strength of sympathetic signaling. Where 
at rest or minimal signal strength AC9 is weakly active and a maximal sympathetic signal 
would lead to full enzymatic activity.  
6.2.4 Whole cell versus in vitro biochemical assessment of AC9 regulation.  
Surprisingly, our data supports an indirect mechanism for most previously 
proposed AC9 regulators. One dilemma is how to access regulatory patterns of AC. For 
years the gold standard was expression of AC isoforms in Sf9 cells combined with in 
vitro biochemical assays using purified regulators. However, the importance of 
scaffolding proteins or post translational modifications of AC are lacking in this 
approach. For example, PKA phosphorylation and inhibition of AC5 and AC6 was 
originally detected in membranes or with detergent-solubilized preparations of AC using 
a large excess of kinase; however, regulation of AC5/6 by PKA is readily apparent when 
in complex with AKAP79-PKA (Bauman et al., 2006; Chen et al., 1997; Iwami et al., 
1995). Generally scaffolding proteins simply make these reactions more efficient, thus 
94 
 
we expected to detect any direct PKC regulation of AC9 in vitro using an excess of 
kinase sufficient to activate AC2.  
 To further evaluate differences between my biochemical results and previous 
whole cell experiments, a live-cell cAMP assay was utilized in COS-7 cells. HEK293 
cells are widely used to study AC regulation but they endogenously express multiple AC 
isoforms (1, 2, 3, 5, 6, 7 (weakly), 9, and sAC), which limits their utility (Lefkimmiatis et 
al., 2009). COS-7 cells provided the advantage of using a mammalian cell line, lacking 
expression of Gαi-inhibitable ACs while endogenously expressing AC7 (Premont, 1994) 
and AC9 (representing ~40% of Gαs-stimulated activity). Agonist-stimulation of µOR-
coupled Gi/o receptors significantly inhibited overexpressed AC6 in COS-7 cells, 
demonstrating that these cells have all the necessary components for Gαi/o inhibition. 
The fact that I observed no inhibition of endogenous AC activity or AC9 overexpressed 
activity in whole-cells by µOR receptors further supports the lack of direct regulation of 
AC9 by Gαi/o.  
6.2.5 AC homo- and heterodimerization 
Numerous studies have suggested that AC isoforms form homodimers based on 
mutational complementation (AC1), cooperative activation (AC5) or co-
immunoprecipitation and FRET studies (AC6 and AC8) (Chen-Goodspeed et al., 2005; 
Gu et al., 2002; Tang et al., 1995). Weak heteromeric formation was reported for AC8 
with AC6 (Gu et al., 2002). Evaluation of AC8 homodimers suggests that loss of activity 
in AC8 mutants can be partially rescue when co-expressed with WT AC8. Structurally, 
it is thought that oligomers are formed through interactions of the transmembrane 
domains (Gu et al., 2002). I now show that AC9 not only forms homodimers but can also 
form heteromers with the Gαi-regulated isoforms AC5 and AC6. The ability of AC9 to 
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form heteromers may explain why studying AC9 regulation in cell lines that express 
multiple AC isoforms (i.e. HEK293 cells) has proven difficult.  
At this time the physiological importance of AC homo- and heterodimers is 
unclear. It is tempting to speculate that dimerization of AC9 with AC5/6 could potentially 
result in Gαi/o inhibition of the complex or even AC9. Heteromer formation may also 
explain why a reduction of both Gαs- and forskolin-regulated activity is observed upon 
knockdown or knockout of AC9; given the relative forskolin insensitivity of AC9, we 
would have expected minimal loss of forskolin-stimulated activity.  
More recently, AC5 was shown to interact via its transmembrane helices with 
adenosine (A2AR) and dopamine (D2R) receptors in striatal neurons; the functional pre-
coupling of this complex was suggested to be necessary to promote canonical Gs-Gi 
regulation of AC5. Minimally this complex should be composed of two AC5 molecules 
with two heterotetramers of A2AR-D2R. (Navarro et al., 2018). It is easy to imagine tissue 
dependent variations of this pre-coupled complex. In heart pre-coupled complexes of 
AC5/6-Gi:GPCR with AC9-Gs:GPCR (Figure 28) could facilitate integration of Gs and 
Gi regulation. Also, in heart, stimulation of the β-adrenergic receptor enhances 
phosphorylation of Hsp20 in a cAMP-PKA dependent manner (Fan et al., 2004). While 
a Gi:GPCR has not been directly implicated in reducing Hsp20 phosphorylation, altering 
cAMP pools by inhibiting PDEs enhances phosphorylation and inhibiting PKA reduces 
phosphorylation (Fan et al., 2004; Martin et al., 2014). It is not outside the realm of 
possibilities that activation of a Gi:GPCR could similarly reduce Hsp20 phosphorylation. 
Based on the finding that deletion of AC9 only reduced Hsp20 associated AC activity in 
heart by 30%, we expect that Hsp20 associates with another AC isoform; the most likely 
candidates being AC5/6. It would be interesting to see whether a pre-coupled AC dimer 
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complex contributes to the phosphorylation status of Hsp20 or other proteins regulated 
by Gs and Gi. Oligomerization of ACs may present another mechanism to fine tune 
regulation of local pools of cAMP and facilitate cross-talk between signaling pathways.  
 
 
 
 
 
Figure 28. Pre-coupled AC-dimer complex. 
 
6.3 From complex to physiological function 
An underlying theme that appears from examination of cardiac phenotypes in 
AC9-/- mice is that physiological roles of AC9 are vastly dependent on association with 
macromolecular complexes and tissue distribution (Figure 29). Knockout of either of the  
Figure 29. Role of AC9-containing complexes in cardiac physiology.  
AC9 expression in the heart is observed in the sinoatrial node (SAN), left ventricle, and 
right atrium. Contributions of AC9 to cardiac function are dependent on tissue 
localization and complex formation. Interaction of AC9-Popdc-TREK is hypothesized to 
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contribute to heart rate control in the SAN. Whereas in the left ventricle AC9-Hsp20 is 
predicted to play a role in cardiac stress response and the AC9-Yotiao-KNCQ1 complex 
contributes to repolarization in both ventricles. Parts of this figure are modified from: 
Baldwin, T. A., and C. W. Dessauer. 2018. Function of Adenylyl Cyclase in Heart: the 
AKAP Connection. J Cardiovasc Dev Dis 5. distributed under the Creative Commons 
Attribution License (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/.  
 
major cardiac AC isoforms (AC5 or AC6) significantly reduce total cAMP levels whereas, 
deletion of AC9 contributes minimally to total cardiac AC activity. Contributions of AC9 
could only be revealed in the presence of SQ 22,536, a P-site inhibitor that display > 
100 fold selectivity for AC5/6 compared to AC9 (Brand et al., 2013; Li et al., 2017b). 
Using cardiac membrane from WT or AC9-/- mice, Gs dose response curves were 
generated with SQ 22,536 revealing that AC9 represents ~3% of Gαs stimulated AC 
activity. It should be noted that this estimate represents the upper limit for AC9 
contribution to total AC activity. Despite this, immunoprecipitated Yotiao associated AC 
activity, (Bauman et al., 2006; Kapiloff et al., 2009; Piggott et al., 2008), was abolished 
in AC9-/- heart lysates, confirming that in heart only AC9 can associated with Yotiao 
(Piggott et al., 2008). AKAP150 associated AC activity was unaltered in AC9-/-; 
suggesting that AC5 and AC6 are the largest contributors of cAMP to the AKAP79/150 
local pool (Efendiev et al., 2010; Nichols et al., 2010). Similar to alterations in total cAMP, 
AC9-/- minimally altered global PKA signaling, although it was important for specific 
signaling in local complexes. Basal phosphorylation of the small heat shock protein 20 
(Hsp20) was reduced in AC9-/- heart lysates. AC9-Hsp20 association was demonstrated 
by immunoprecipitation and proximity ligation assays and shown the interaction occurs 
independently of Yotiao.  
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6.3.1 Cardiac repolarization (AC9-Yotiao-KCNQ1)  
As the only cardiac AC isoform associated with the Yotiao-KCNQ1 complex, it 
was of interest to see whether evidence of AC9 contribution to cardiac repolarization 
could be observed in vivo. Patients with mutations in KCNQ1 (LQT1) have reported 
bradycardia phenotypes exacerbated by physical activity, swimming in particular 
(Schwartz et al., 2008; Swan et al., 1999). Although, resting bradycardia phenotypes 
are typically associated with LQT3,4, or 10 (Amin and Wilde, 2018). A bradycardia 
phenotype is observed in AC9-/- with no observed prolongation of the QT interval in 
anesthetized mice. Association of this phenotype with IKs in mice is complicated. While 
the IKs channel is critical for late phase repolarization in humans and AC9 association 
with Yotiao sensitizes phosphorylation of IKs in vitro, adult mice do not express a 
functional channel (Honore et al., 1991; Marx et al., 2002; Salama et al., 2009). It is 
possible the observed bradycardia results from alterations in an unidentified Yotiao-AC9 
associated potassium channel. Possible candidates include IK type channels expressed 
in mouse, IK, slow1/2 (Nerbonne and Kass, 2005). Expression of dominant negative IK, slow1 
or IK, slow2 in mouse both result in prolonged QT intervals (Li et al., 2004; Xu et al., 1999).    
Clinically, beta blockers are used to treat LQTS (Schwartz, 2006) with a high 
degree of success (Hobbs et al., 2006; Itoh et al., 2001), but do not abrogate symptoms 
for all patients (Priori et al., 2004). Recent efforts to treat arrhythmias have focus on 
defining macromolecular complexes that modulate ion channel function. AC9 enhances 
IKs channel activity when bound to Yotiao by sensitizing PKA phosphorylation of KCNQ1 
in response to b adrenergic stimulation in vitro (Li et al., 2012). It is conceivable that 
AC9 could be targeted for treatment of LQTS. While conceivable, effectiveness would 
be dependent on type of LQTS. Targeting AC9 activity could not overcome disruption of 
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macromolecular complex formation in mutations that disrupt the binding of Yotiao and 
KCNQ1.  
6.3.2 Cardiac stress (AC9-Hsp20) 
Hsp20 has a well-documented cardioprotective role in heart, protecting against 
various insults including doxorubicin cardiotoxicity, ischemia/reperfusion injury, and 
prolonged beta-agonist induced hypertrophy (Fan et al., 2006; Fan et al., 2008; Martin 
et al., 2014). Hsp20 is phosphorylated by protein kinase A (PKA) in response to b-
adrenergic stimulation is critical for its cardioprotective role. In response to chronic b-
adrenergic stimulation Hsp20 phosphorylation confers cardioprotection by attenuating 
detrimental cardiac remodeling in mouse models (Fan et al., 2006). Hsp20 is also 
suggested to protect against human heart failure. Total and phosphorylated Hsp20 are 
upregulated in human failing hearts by ~2-fold compared controls (Qian et al., 2009). 
The phosphorylation level of Hsp20 is controlled and facilitated by formation of a 
macromolecular complex. Regulators of Hsp20 either bind directly (PP1(Qian et al., 
2011) or to phosphodiesterase 4D (PDE4D) (Martin et al., 2014)), or complex with 
Hsp20 through the scaffold, A-kinase anchoring protein-Lbc (AKAP-Lbc) (Edwards et 
al., 2012a). The binding of PDE4D to Hsp20 decreases phosphorylation through 
degradation of cAMP; disrupting PDE4D-Hsp20 association enhances phosphorylation 
and protects against pathological remodeling (Martin et al., 2014). Binding to Hsp20 
AKAP-Lbc promotes phosphorylation through coordinating PKA and is cardioprotective 
in neonatal rat cardiomyocytes (Edwards et al., 2012a). Cardioprotection by 
phosphorylated Hsp20 is suggested to occur by enhancing cardiac function through 
regulation of relaxation and contraction (Fan et al., 2005b). At the molecular level, Hsp20 
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influences calcium handling, promoting the phosphorylation of phospholamban (PLN) 
by inhibiting the activity of protein phosphatase 1 (PP1) (Qian et al., 2011).  
AC9 interaction with Hsp20 adds an additional mode for controlling Hsp20 
phosphorylation. Basal phosphorylation of Hsp20 at Ser16 is markedly reduced in AC9-
/- mice. Whether AC9 associates with Hsp20 in a novel complex or with previously 
defined Hsp20 complexes is unclear. Although, Hsp20 associated activity is reduced in 
AC9-/- mice it is not abolished like Yotiao associated activity. We expected that Hsp20 
interacts with other cardiac AC isoforms. Further evidence for AC9 maintaining 
phosphorylation levels of Hsp20 is observed in neonatal cardiomyocytes expressing 
catalytically inactive AC9 (AC9d), which attenuates isoproterenol induced 
phosphorylation of Hsp20. Expression of AC9d appears to work as a dominant negative 
disrupting Hsp20 association with endogenous WT AC9 and/or other AC isoforms.     
Cardiac phenotyping of AC9-/- reveals altered diastolic relaxation with pulsed 
wave and tissue Doppler measurements. The E/A ratio is significantly reduced due 
primarily to attenuation of early filling phase velocity (E wave). Although diastolic 
dysfunction can be observed in LQT1 and LQT2 (Leren et al., 2015), I hesitate to 
speculate that diastolic dysfunction in AC9-/- mice is simply due to distorted channel 
regulation. Alternatively, AC9 dependent alterations in Hsp20 phosphorylation could 
underlie this phenotype. Cardiac remodeling and fibrosis also cause diastolic 
dysfunction from stiffening of the left ventricle. Hsp20 promotes pathological remodeling 
and fibrosis by facilitating protein kinase D1 (PKD1) translocation to the nucleus which 
initiates the fetal gene program (Sin et al., 2015). Disruption of this complex retards 
pathological phenotypes. The importance of Hsp20 phosphorylation in this process is 
unknown.   
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Additional evidence for a cardioprotective role of AC9 comes from observations 
of upregulated levels of the micro RNA which regulates AC9 (miR-142-3p) in human 
(non-ischemic dilated cardiomyopathy) and mouse model (hypertrophic 
cardiomyopathy) cardiac pathologies (Bagnall et al., 2012; Baskerville and Bartel, 2005; 
Tijsen et al., 2012; Voellenkle et al., 2010).  
6.3.3 Heart rate control (AC9-Popdc-TREK) 
 The AC9-Yotiao-IK complex represents one possible mechanism underlying the 
bradycardia phenotype. Another possibility is the AC9-Popdc-TREK complex. TREK 
functions as a leak potassium channel that maintains the resting membrane potential in 
addition to modulating action potentials (Honore et al., 1991) and has recently been 
shown to be important for maintaining sinoatrial node excitability in mice (Unudurthi et 
al., 2016). Popdc promotes localization of TREK at the plasma membrane increasing 
channel activity two-fold (Froese et al., 2012). These effects are lost when Popdc binds 
cAMP. TREK currents are also attenuated by PKA phosphorylation (Terrenoire et al., 
2001). It has been suggested that the effect of cAMP bound Popdc represents a second 
mechanism for reducing TREK current (Froese et al., 2012). It may be hypothesized that 
AC9 drives one or both of these mechanisms by enhancing cAMP binding to Popdc and 
PKA phosphorylation of the channel. Additionally, I would add to this and hypothesis 
that cAMP bound Popdc-AC interactions create a negative feedback loop that could 
contribute to spatial and temporal components of this signaling pathway. Contrary to 
what I would have predicted, the TREK knockout mice display a bradycardia phenotype. 
Although, authors conclude that this phenotype is due to compensatory changes in 
sympathetic and parasympathetic regulation as the intrinsic heart rate is unaltered 
(Unudurthi et al., 2016). 
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6.4 Future directions 
As the most divergent membrane bound AC, my further exploration in to the 
regulation and physiological roles of AC9 have opened the door to novel and exciting 
research questions in the AC signaling field.  
 First, an understanding of AC9 regulation in vivo is still in its infancy. It was 
surprising that my findings suggest only Gas directly regulates AC9. All of the other 
membrane bound isoforms have multiple regulation mechanisms (Dessauer et al., 
2017). Initial looks into AC9 regulation utilized whole cell assay which could have 
provided components necessary for direct or indirect AC9 regulation such as scaffolds. 
While I have clearly shown AC9 is not inhibited by Gai/o, other modes of AC9 regulation 
were not as closely examined and could simply require a scaffold to localize AC9 with 
the upstream regulator. It is also possible that additional regulators of AC9 have not 
been identified. The ability of AC9 to homo- and heterodimerization is particularly 
intriguing although at this time I can only speculate that this may contribute to overall 
complex regulation or AC9 regulation and subsequent production of local cAMP pools. 
Identifying the binding sites of oligomerization is particularly important for further 
examination of these complexes.  
While intriguing, the observed bradycardia phenotype in AC9-/- mice requires further 
validation. The caveat to the described heart rate measurements is that they were 
conducted with anesthetized mice; anesthesia has well known effects on heart rate (Ho 
et al., 2011). Currently, studies are underway to implant telemetry units to determine 
whether the bradycardia phenotype can be recapitulated in a conscious mouse model. 
We will not only examine alterations in basal heart rate but utilize various stressors 
(treadmill, forced swim test, and isoproterenol injection) to see whether AC9 knockout 
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also displays a stress induced bradycardia similar to Popdc knockout (Froese et al., 
2012). It is also unclear whether the observed diastolic dysfunction in AC9-/- is due to 
alterations in repolarization and subsequent mechanical dysfunction (De Ferrari and 
Schwartz, 2009; Haugaa et al., 2009), Hsp20 dependent fibrosis (Fan et al., 2006; Martin 
et al., 2014; Sin et al., 2015), or an alternative mechanism.  
A role for AC9 in cardioprotection was postulated based upon alterations of basal 
Hsp20 phosphorylation. The importance of Hsp20 phosphorylation has primarily been 
established in response to cardiac stress models (prolong b-agonist stimulation, 
transverse aortic construction, ischemia/reperfusion, and cardiotoxic drugs), further 
studies should examine whether AC9 is cardioprotective in similar stress models and 
determine whether there are other proteins associated with this complex.   
The absence of IKs in adult mice allowed me to evaluate whether AC9 has alterative 
roles in cardiac function outside of sensitizing IKs phosphorylation. Although, this 
complicated the analysis of whether AC9 contributed to cardiac repolarization. The 
importance of AC9 for sensitizing phosphorylation of IKs and repolarization in vivo still 
needs to be evaluated. Current work by others in the lab is using a transgenic IKs mouse 
model crossed with AC9-/- to examine this.  
My findings indicate Popdc is a novel AC scaffold, regulator, and downstream 
effector synthesized into one protein. While AKAPs are the most studied AC scaffold 
they function as a scaffold that regulates ACs indirectly via scaffolding of PKA, and 
anchor downstream effectors. There are a number of important questions to ask in 
regard to this interaction. How to Popdc-AC interact? My findings would indicate this 
likely occurs through the Popdc transmembrane domains or near transmembrane 
domain. Do ACs bind to Popdc homo- or heterodimers (Knight et al., 2003; Schindler, 
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2013; Vasavada et al., 2004)? The presented findings are evaluated in HEK293 cells, 
which endogenously express Popdc1. It is possible that the interaction of ACs with 
Popdc2 in this system could be dependent on Popdc1-Popdc2 heterodimers. Popdc 
also represents the first direct negative regulator of AC9. Further studies are required to 
understand the mechanism of Popdc inhibition and how cAMP contributes to this. 
Additionally, Popdcs facilitates membrane localization of TREK and binds various 
proteins involved in trafficking. It would also be of interest to see whether Popdc alters 
membrane localization or trafficking of ACs. 
 In summary, my findings show definitively that AC9 is not inhibited by Gai/o and 
suggest that regulation by Gbg, PKCbII, or CaMKII occur indirectly. Interestingly, AC9 
can form both homodimers and heterodimers with Gai/o sensitive isoforms (AC5/6); 
although, the physiological relevance of these interactions is unclear. In heart, deletion 
of AC9 results in bradycardia and diastolic dysfunction phenotypes likely due to the 
disruption of AC9 containing complexes. Despite contributing minimally to global cAMP 
in heart, our evidence suggests that AC9 containing complexes are critical for distinct 
components of cardiac physiology. AC9 is the only isoform that contributes to cAMP 
synthesis in Yotiao-dependent complexes, which are essential for cardiac repolarization. 
The importance of this interaction to facilitate signaling is further emphasized by the 
decreased sensitivity of AC9 to Gas observed in vitro. Additionally, AC9 contributes to 
basal AC activity that  regulates baseline  phosphorylation of Hsp20 and cardiac stress 
response. My findings also suggest a mechanism for AC9 involvement in heart rate 
control through an interaction with Popdc, which we propose is a novel regulator and 
scaffold of AC. Overall, my work supports the idea that the role and regulation of AC9 is 
fundamentally driven through associations with various macromolecular complexes. 
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